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Abstract 
Lepin, an adipocyte hormone which functions as the afferent signal in a negative 
feedback loop regulating energy balance, has profound effects on glucose and lipid 
metabolisms. Lipodystrophic humans and mice have a complete or partial absence of 
adipose tissue and a secondary reduction of leptin. This is associated with insulin 
resistance and hepatic steatosis, which are corrected by leptin administration. This thesis 
aimed to define the site of leptin action and understand the molecular basis of leptin's 
insulin sensitizing and antisteatotic effects in lipodystrophy. 
To determine the site of leptin action, we treated lipodystrophic aP2-nSREBP-lc 
mice with a low dose of intracerebroventricular (icv) leptin. These studies showed that 
leptin acts on the brain mediating its peripheral effects indirectly via the CNS. The 
efferent pathways mediating leptin's peripheral effects are currently unknown. Using 
mice with a knockout of all three p-adrenergic receptors, we showed that sympathetic 
nervous system, specifically p-adrenergic receptors are in part responsible for mediating 
leptin's peripheral effects. 
Using microarray analysis in livers of lipodystrophic animals treated with either 
icv or subcutaneous leptin, we determined that central leptin administration repressed 
stearoyl-CoA desaturase-1 (SCD-1) mRNA levels and enzymatic activity. We then 
studied SCD-1 s role in leptin-mediated correction of hepatic steatosis and insulin 
resistance by generating aP2-nSREBP-lc mice homozygous for SCD-1 deletion. These 
animals had reduced hepatic steatosis. We showed that the mechanism by which SCD-1 
deficiency leads to improved hepatic steatosis involved increased AMPK 
phosphorylation in parallel with decreased ACC activity. The latter resulted in decreased 
1 
malonyl C o A levels and increased CPT-1 activity. SCD-1 deficient lipodystrophic 
animals remained diabetic. 
To understand the mechanism of leptin's insulin sensitizing effects, we performed 
a leptin dose-response curve. We identified suboptimal leptin doses which improved 
hyperglycemia and hyperinsulinemia in aP2-nSREBP-lc mice but did not substantially 
alter hepatic steatosis. One of these leptin doses improved insulin-stimulated insulin 
receptor and insulin receptor substrate 2 (IRS-2) phosphorylation, IRS-2-associated PI3K 
and Akt activity in liver suggesting that leptin improved insulin resistance via an insulin-
dependent pathway. To identify leptin-regulated genes important in leptin's insulin 
sensitizing effects, we used cluster analysis of hepatic gene expression with several 
peripheral leptin doses. 
Chapter 1: Introduction 
Diabetes as a medical problem 
Consequences of diabetes 
Diabetes, formerly considered a minor health issue, has become a major health 
problem over the past years (Zimmet 2000). Worldwide, there is an increasing number of 
people diagnosed with diabetes every year. Furthermore, diabetes together with obesity 
has now become the epidemic of the 21st century (Zimmet et al. 2001). It is expected that 
by year 2020, there will be approximately 250 million people worldwide diagnosed with 
non-insulin dependent diabetes mellitus (O'Rahilly 1997). This is a 46% increase from 
the current number of diabetics worldwide (Zimmet et al. 2001). Furthermore, there is an 
alarming increase in the number of cases of children and young people affected by non-
insulin dependent diabetes mellitus (Zimmet et al. 2001). With this epidemic increase in 
diabetes, this disease is now a huge burden on the healthcare systems worldwide. It is 
estimated that more than $100 billion are spent on diabetes treatment in the United States 
each year (Ross et al. 2004). 
Diabetes is associated with a number of diseases that increase the morbidity and 
mortality of the affected patients. These include an increased risk for macrovascular 
complications such as coronary artery disease, peripheral arterial disease and 
cerebrovascular disease as well as microvascular complications such as retinopathy, 
nephropathy and neuropathy. In the United States, diabetes is the major cause of limb 
amputations, renal failure and blindness. Atherosclerosis is the primary cause of 
mortality in patients with 
non-insulin dependent 
diabetes mellitus (Ross et 
a 1. 2 0 0 4 )(Figure 
l.l)(Haffheretal. 1998). 
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Figure 1.1 Percantage of diabetics and nondiabetics su.rviving 
coronary heart disease. Kaplan-Meier Estimates of the probability 
of death from coronary heart disease in 1059 subjects with Type 2 
Diabetes and 1378 nondiabetic subjects with and without prior 
myocardial infaction (Taken from Haffner et al. 1998) 
main types of diabetes, type I and type II. Type I diabetes is also known as juvenile 
diabetes or insulin-dependent diabetes mellitus (IDDM). Type I diabetes is caused by 
total insulin deficiency due to the destruction of pancreatic islet p-cells. The destruction 
of p-cells is caused by an autoimmune reaction against the islet cells of the pancreas 
(Devendra et al. 2004). Type I diabetics are dependent on insulin therapy for their 
survival. Even though, the incidence of type I diabetes is also increasing, less than 10% 
of the 16 million diabetics in the United States have type I diabetes (Ross et al. 2004). 
Type II diabetes, non-insulin dependent diabetes mellitus (NIDDM), is the more 
common form of diabetes. Type II diabetes is a complex metabolic disease, which is 
characterized by relative insulin deficiency, decreased insulin action and insulin 
resistance (Ross et al. 2004). Type II diabetes has been increasingly associated with a 
complex number of conditions such as hyperinsulinemia, dyslipidemia, hypertension, and 
visceral obesity (Zimmet et al. 2001). For the rest of this thesis, diabetes will be used in 
order to refer to type II diabetes unless stated otherwise. 
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Other types of diabetes include diabetes associated with monogenic defects in p-
cell function, which usually results in early-onset mild hyperglycemia. These defects 
include mutations in MODY (Maturity Onset Diabetes of the Young) genes such as 
HNFla, PDX-1, NEURO-D1, glucokinase and FINF4a (Stoffel et al. 1992b; Vionnet et 
al. 1992; Stoffel and Duncan 1997; WHO 1999). 
Diabetes mellitus is defined by hyperglycemia: fasting plasma venous glucose 
concentrations of s=7.0 mmol l"1 or plasma venous glucose concentrations al 1.1 mmol l"1 
after a 2-h post-glucose load (Zimmet et al. 2001). People with impaired glucose 
tolerance (IGT) are at a high risk of developing diabetes. According to WHO definitions, 
IGT is described as hyperglycemia where glucose levels are between normal and 
diabetic, which is fasting glucose plasma venous concentrations <7.0 mmol l"1 and 
between 7.8 mmol l"1 and 11.0 mmol l"1 after a 2-h post-glucose load (Zimmet et al. 2001) 
(Table 1 1). 
Impaired fasting 
glucose (IFG) was 
defined by 
American Diabetes 
Association as 
another way of 
measuring glucose 
metabolism for the 
likelihood of 
Table 1 Values for diagnosis* of diabetes and other types of hyperglycaemia 
Glucose concentration (mmol I"') 
Plasma Whole blood 
Venous Capillary Venous Capillary 
Diabetes mellitus 
Fasting 
2-h post-glucose load 
Impaired glucose tolerance 
Fasting concentration 
2-h post-glucose load 
3 7.0 3 7.0 
311.1 312.2 
<7.0 <7.0 
7.8-11.0 8 9-12.1 
3 6.1 3 6.1 
3 10.0 3 11.1 
<6.1 -.6 1 
6.7-9.9 7.8-11.0 
Impaired fasting glucose 
fasting 6.1-6.9 6.1-6.9 5.6-6.0 5.6-6.0 
2-h post-glucose load <7.8 <8.9 <6.7 <7.8 
'Noto that diabetes can be diagnosed in an mdivc;..ai an y when these aiaqnostic values are 
confirmed on an j'her day. Data trom ref. 2<l. 
Ranges of values are inclusive ;:hat is. 6.1 -6.9 irears 5 (? 1 and < 7.0). 
Table 1.1 Definitions of diabetes and hyperglycaemia (Taken from 
Zimmet etal. 2001) 
developing future diabetes ( W H O 2003). 
The Diabetes Epidemic 
Type II diabetes is one of the leading metabolic disorders which affects about 5 to 
10% of most populations and it's prevalence is rapidly growing among developing 
nations (Goldstein 2003). The incidence of type II diabetes is rapidly expanding 
especially in certain populations. Pacific island of Nauru is one of these populations 
where diabetes was a rare disease until recently whereas currently, 40% of adults are 
diabetic (Zimmet et al. 1990). There was a similar increase in the prevalence of diabetes, 
obesity and heart disease among the inhabitants of the Micronesian island of Kosrae 
(Shmulewitz et al. 2001). In the Indian island of Mauritius whose population includes 
Asian Indian, Chinese and Black (Creole) descent people, the prevalence of obesity 
increased two folds and now about 20% of the population above 30 years old are affected 
(Zimmet 2000). Similar trends are also seen among the Singaporean Chinese and 
Taiwanese (Chang et al. 1998; Tan et al. 1999). 
The rising incidence of diabetes is linked closely to the worldwide obesity 
epidemic. According to WHO, an 18-year old lean woman who does not gain weight 
into her adulthood is 80 times less likely to develop diabetes compared to an overweight 
woman who continues to gain weight. With the increasing number of children and young 
people developing obesity, diabetes is now a significant health issue among children and 
youth (Zimmet et al. 2001). There are several reports of diabetic children from Japan, 
US, Pacific Islands, Hong Kong, Australia and the UK. For example, in Japan, type II 
diabetes in children increased considerably, currently in this country, 80% of children 
with diabetes are type II diabetics (Zimmet et al. 2001). 
Causes of diabetes 
A n epidemic due to nature or nurture? 
Diabetes is a disease of glucose metabolism in which insulin action on insulin 
sensitive peripheral tissues is impaired due to insulin resistance and defective insulin 
secretion by pancreatic P-cells. Diabetes is a complex disorder, which involves an 
interplay between genetic and environmental factors. Diabetes is likely to be the result of 
several genes interacting with each other and with several environmental factors thus 
resulting in this complex disease. 
Emergence of obesity and hence the diabetes epidemics is largely blamed on the 
"western" diet and lifestyle which is also adapted by many third world countries. The 
reason for some ethnic populations to have such a high prevalence of these epidemics is 
thought to be due to their genetic susceptibilities. These already existing susceptibility 
genes when combined with the new environmental factors result in these high disease 
incidences (Zimmet 2000). The increase in childhood and youth obesity and diabetes 
epidemics are also largely blamed on the changes in children s and youths's habits and 
diets. Nowadays, children are spending less time doing physical activities and more time 
sitting in front of television and consuming high fat, high calorie food products. For 
example, studies among young Japanese people showed that they are participating less 
and less in exercise and sports. Similar studies in the US showed that 27% of high school 
girls and 43% of boys do not engage in sufficient amount of physical activity 
(Bloomgarden 2004). 
"Thrifty genotype" hypothesis aims to explain the apparent differential 
susceptibility of certain ethnic groups or populations for developing obesity and diabetes. 
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According to this hypothesis, during evolution, certain populations and ethnic groups, 
especially the ones, which went through periods of famine or natural disasters were 
selected for these susceptibility genes that enabled them to store and conserve more fat as 
an energy resource. However, in this century where high fat food is plentiful and easy to 
obtain, these individuals have a much higher risk of developing obesity and diabetes 
(Neel 1962). 
"Thrifty phenotype" hypothesis on the other hand aims to explain the association 
between low birth weight with the increased likelihood of developing obesity, diabetes 
and hypertension as an adult. According to this hypothesis, a decreased birth size 
indicates malnutrition in the uterus, which causes permanent structural and functional 
changes that predispose such individuals to metabolic diseases such as obesity and 
diabetes (Hales and Barker 1992). 
Even though environmental factors are clearly very important for the pathogenesis 
of diabetes, genetic factors are as important. For example, in two genetic models of 
obesity and diabetes, ob/ob and db/db mice, early experiments suggested the presence of 
a soluble factor, which was missing in ob/ob mice and its receptor that was missing in 
db/db mice as the reason for the obesity and diabetes of these animals (Coleman 1973). 
This soluble factor, an adipocyte hormone named leptin and its receptor, leptin receptor 
were cloned in 1994 further conforming that both obesity and diabetes have a strong 
genetic basis (Zhang et al. 1994; Tartaglia et al. 1995). 
Genetic causes of diabetes 
While environmental factors clearly influence the pathogenesis of diabetes, 
genetic factors are as important for the development of this disease. Monogenic forms of 
diabetes as well as twin and sibling studies clearly show the importance of genetic factors 
in the development of diabetes. Family history has been shown to be an important 
determinant in the pathogenesis of this disease. Siblings are 30-40% more likely to 
develop diabetes relative to the 7% likelihood in the general population. Furthermore, 
monozygotic twins are much more likely to develop diabetes compared to dizygotic twins 
(Florez et al. 2003). 
A number of single gene defects have been identified that cause p-cell diabetes 
and insulin resistance. For example, single gene mutations that cause p-cell diabetes 
have been identified in patients with MODY. MODY genes include hepatocyte nuclear 
factor 4a (HNF4a), glucokinase, hepatocyte nuclear factor la (HNFla), insulin 
promoter factor 1, hepatocyte nuclear factor ip (HNFip) and neurogenic differentiation 1 
(NEUROD1). 
A number of single gene mutations that cause insulin resistance were also 
identified in other genes such as seipin, l-acylglycerol-3-phosphate-O-acyltransferase, 
lamin A/C which cause congenital lipodystrophies in humans with metabolic 
abnormalities such as diabetes and insulin resistance. Mutations in the insulin and insulin 
receptor genes themselves were also identified in diabetic humans. Furthermore, a rare 
maternally inherited form of diabetes is caused by a mutation in the mitochondrial gene 
for transfer RNA for leucine. This gene is important for the transcription of genes 
important in oxidative phosphorylation in mitochondria (Florez et al. 2003). 
A number of susceptibility genes for diabetes were also identified. One of these 
genes is calpain 10 gene, which was identified in diabetic Mexican Americans. 
Polymorphisms in other genes such as peroxisome proliferator-activated receptor y 
(PPARy), sulfonylurea receptor, glucagon receptor, glucokinase, glucose transporter 
GLUT1 and potassium inward rectifier channel K.j-6.2 were also associated with diabetes 
(Florez et al. 2003; Bloomgarden 2004). Recently, a mutation in the protein kinase 
Akt2/PKBp gene was identified in a family, which has a dominant inheritance of severe 
insulin resistance and diabetes mellitus (George et al. 2004). 
Even though mutations in several genes were identified in rare monogenic forms 
of diabetes, these mutations only explain a very small proportion of the common diabetes 
seen in rest of the population; therefore, genes that cause the common form of diabetes 
still remain to be identified. It is therefore critical to define the molecular basis for 
glucose metabolism. 
Glucose metabolism 
Role of insulin in glucose metabolism 
Banting and Best discovered insulin as the glucose-lowering hormone about 80 
years ago. Since its discovery, insulin has not only saved many patients with diabetes but 
also opened the doors for researchers who have been trying to understand the molecular 
mechanisms for glucose homeostasis. 
We now know that insulin is secreted from pancreatic islet p-cells upon 
carbohydrate intake and it acts on insulin sensitive tissues such as muscle and adipose 
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tissue in order to promote glucose uptake into these tissues. Insulin signaling was found 
to activate the translocation of glucose transporters, mainly isotope 4, GLUT4, onto the 
cell membrane thereby facilitating glucose uptake into these tissues where it gets 
metabolized for ATP, NADPH, ribose phosphate, hexosamine production and for 
glycogen synthesis (Cushman and Wardzala 1980; Suzuki and Kono 1980; Ziel et al. 
1988; Ren et al. 1993; Ross et al. 2004). This is a key action of insulin since this step 
was shown to be defective in diabetic states where insulin stimulated Glut4 translocation 
in muscle and adipose tissue is impaired. 
Animal models of Glut4 deficiency or overexpression also confirmed the 
important role of this molecule in glucose homeostasis. Although a global knockout of 
Glut4 did not have a diabetic phenotype, these mice were somewhat insulin resistant 
(Katz et al. 1995). It is likely that other glucose transporter isotypes compensate for the 
loss of Glut4 in this model. When Glut4 gene was knocked out in a tissue-specific 
manner using the cre-lox system, both the muscle-specific and the adipose tissue specific 
knockout mice were severely insulin resistant (Zisman et al. 2000; Kim et al. 2001) (Abel 
et al. 2001). Furthermore, mice overexpressing Glut4 in muscle have increased glucose 
transport and metabolism in muscle (Liu et al. 1993; Hansen et al. 1995). When these 
transgenic mice were crossed to the leptin receptor mutant db/db mice, which exert both 
obesity and diabetes, the diabetic phenotype of the db/db mice was improved. These 
animals showed lower plasma glucose levels and increased insulin sensitivity (Brozinick 
et al. 2001). These studies established the importance of insulin mediated Glut4 
translocation in glucose homeostasis; however, the exact mechanisms by which insulin 
stimulates this translocation are currently under investigation. 
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Once glucose is taken into the cell, it is converted to glucose-6-phosphate either 
by hexokinase or glucokinase enzymes. At this step, some of the glucose is oxidized to 
produce energy for the cell and the rest is converted to glycogen by glycogen synthase. 
Insulin activates protein phosphatase 1 (PPI) which dephosphorylates and hence activates 
glycogen synthase. At the same time, insulin inhibits two other enzymes, protein kinase 
A (PKA) and glycogen synthase kinase-3 (GSK-3), which phosphorylate and hence 
inactivate glycogen synthase (Ross et al. 2004). 
In addition to stimulating glucose uptake into muscle and adipose tissue and 
increasing glycogen synthesis, insulin also acts on liver to affect glucose metabolism. 
Glucose is an essential energy source for many organs such as the brain. Plasma glucose 
levels are kept constant in between meals by glucose release from the liver (hepatic 
glucose output). There are two pathways by which liver releases glucose: 
Gluconeogenesis and glycogenolysis. Gluconeogenesis is the de novo synthesis of 
glucose from smaller precursors such as glycerol, lactate, alanine and pyruvate. 
Glycogenolysis is the release of glucose from glycogen stores. Upon acting on liver, 
insulin inhibits hepatic glucose output. Insulin controls gluconeogenesis through 
transcriptional regulation of gluconeogenic genes in liver. The expression of two key 
enzymes in gluconeogenesis, phosphoenolypyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase (G6Pase) are transcriptionally controlled. Peroxisome 
proliferator-activated receptor gamma coactivator 1 (PGC-1) and forkhead transcription 
factors are implicated to have a role in this regulation (Nakae et al. 1999; Yoon et al. 
2001). In liver, insulin also enhances glucose oxidation via transcriptional activation of 
glycolytic genes such as pyruvate kinase and glucokinase. 
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In diabetes, glucose uptake into muscle and adipose tissue, as well as inhibition of 
hepatic glucose output upon insulin stimulation are impaired. Both of these defects 
contribute to hyperglycemia observed in diabetes. Furthermore, insulin secretion from 
the pancreatic islet P-cells also becomes defective in this disease. 
Insulin signal transduction pathway 
Insulin receptor (IR) is a receptor tyrosine kinase that forms a heterotetramer of 
two a and two p subunits. Upon insulin binding, a conformational change occurs which 
enables the a subunit, which under basal conditions allosterically inhibits the p subunit; 
relieve its inhibition on the p subunit. Specific tyrosine residues on the p subunit then get 
transphoshorylated, which leads to the activation of the tyrosine kinase activity of the 
receptor that may now phosphorylate substrate molecules. Three tyrosine residues in the 
P subunit, Tyr-1146, Tyr-1162 and Tyr-1163, were identified as being critical for insulin 
signaling (Wilden et al. 1990). Insulin receptor is essential for a number of insulin 
mediated biological events. Humans have been identified with mutations in insulin 
receptor gene, which abolishes the kinase domain of this receptor. These individuals 
develop diabetes as well as a number of other cellular defects (Taira et al. 1989). 
Moreover, even though global IR knockout mice develop normally in uterus, they die 
shortly after birth due to severe hyperglycemia and hyperketonaemia (Accili et al. 1996; 
Kadowaki 2000). Tissue specific knockouts of IR were also made in order to study the 
relative importance of IR signaling in various tissues. Muscle-specific IR knockout mice 
have increased adipose tissue, elevated levels of serum triglycerides and free fatty acids 
as well as insulin resistance similar to metabolic syndrome. These mice have normal 
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plasma glucose and insulin levels and have normal glucose tolerance. It should however 
be noted that these animals do not have a complete reduction of the IR (Bruning et al. 
1998). Adipose tissue specific IR knockout mice on the other hand, have decreased 
adiposity, increased lipolysis and they do not have a diabetic phenotype (Bluher et al. 
2002). Liver-specific IR knockout mice develop a severe insulin resistance, 
hyperglycemia and hyperinsulinemia. In these mice, insulin also fails to suppress 
gluconeogenesis (Michael et al. 2000). Neuron specific IR knockout mice on the other 
hand, develop obesity with mild insulin resistance. These animals also have impaired 
fertility (Bruning et al. 2000). Pancreatic (3-cell specific insulin receptor knockout mice 
surprisingly only develops a mild diabetic phenotype (Kadowaki 2000; Nandi et al. 
2004). 
The first insulin receptor substrate identified was insulin receptor substrate-1 
(IRS-1) (Keller et al. 
1991; Sun et al. 
1991; Keller et al. 
1993). Later, 
several other insulin 
receptor substrates 
including IRS1-4, 
Dok, Gab-1, Cbl, 
APS and She 
isoforms, were also 
identified. IRS-1 is 
Insulin 
Insulin Receptor 
GSK3 
SGK AKT 
Foxo 
pT0S6K BAD 
PDE3b 
Figure 1.2 Insulin signaling molecules. (Taken from Nandi et 
al., 2004) 
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a 160kDa docking protein, which gets phosphorylated on several tyrosine residues upon 
insulin binding to its receptor. There are a number of proteins with src homology 2 (SH2) 
domain which then dock on these phosphorylated tyrosine residues on insulin substrate 
molecules to further relay insulin signaling. Some of these docking proteins include 
PDK, Nek, Grb2 and Crkll, which might either act as adapter molecules or carry out 
enzymatic functions themselves (Ross et al. 2004). 
Animal knockout studies further indicated the importance of the IRS molecules in 
insulin mediated signaling and that these molecules are probably not redundant but 
complementary in nature. IRS-1 knockout mice have peripheral insulin resistance as well 
as impaired glucose tolerance and pre- and postnatal growth retardation (Araki et al. 
1994; Tamemoto et al. 1994). IRS-2 knockout mice show more of a type II diabetic 
phenotype with peripheral insulin resistance, hepatic insulin resistance and diminished p-
cell mass (Withers et al. 1998). IRS-3 and IRS-4 knockout mice on the other hand do not 
show a diabetic phenotype (Liu et al. 1999; Fantin et al. 2000). The exact roles of these 
two molecules are not well understood. Since diabetes is a poly genetic disease, in order 
to study the contribution of several genes in insulin signaling and diabetes, researchers 
generated double heterozygote mutants of IR, IRS-1 and IRS-2. Global double 
heterozygous knockouts of IR and IRS-1 mice had significantly higher insulin levels and 
they developed late onset diabetes. The fact that these animals had 5-50 times higher 
insulin levels when each protein was half of normal suggested that these proteins act in 
synergy (Bruning et al. 1997). When double knockouts of IR/IRS-1 and IR/IRS-2 were 
generated, both of these mouse models had muscle insulin resistance, albeit more severe 
in IR/IRS-1 knockout mice (Bruning et al. 1997). These studies suggested that IRS-2 
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isoform is particularly important for hepatic insulin signaling whereas IRS-1 isoform is 
more important in muscle. Mice lacking both IRS-1 and IRS-2 molecules are embryonic 
lethal (Nandi et al. 2004) whereas mice lacking both IRS-1 and IRS-3 molecules develop 
lipoatrophy with insulin resistance but they do not develop hepatic steatosis (Laustsen et 
al. 2002) and mice lacking both IRS-1 and IRS-4 molecules have almost the same 
phenotype as IRS1 knockout mice (Nandi et al. 2004). 
One of the critical downstream mediators of insulin action is phosphatidylinostiol 
3-kinase (PI3K). PI3K has two protein subunits 85 and 1 lOkDa, p85 and pl 10. p85 has 
an SH2 domain, which associates with tyrosine phoshorylated IRS molecules. This 
association then activates the catalytic pl 10 domain. Catalytic pl 10 then phosphorylates 
phosphatidylinositol 4-phosphate and phosphatidylinositiol 4,5-bisphosphate forming 
phosphotidylinositiol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate 
(Ross et al. 2004). Several studies suggested the importance of the above mechanism in 
insulin stimulated glucose transport via Glut4 translocation. In cell culture studies, PI3 
inhibitors, wortmannin and LY-294002, as well as dominant negative PI3 mutants were 
shown to completely block insulin stimulated Glut4 translocation and glucose transport 
(Cheatham et al. 1994; Okada et al. 1994; Haruta et al. 1995; Kotani et al. 1995; Katagiri 
et al. 1997). Other studies where PI3K was either overexpressed or a constitutively 
active form was used, showed increased Glut4 vesicle translocation and glucose uptake 
(Frevert and Kahn 1997) (Martin et al. 1996). The molecular link between PDK 
activation and Glut4 translocation still remains unknown. 
A number of signaling molecules act downstream of PDK in order to relay insulin 
signal transduction. One of these molecules is Akt or protein kinase B, which is a serine/ 
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threonine kinase. Insulin activates Akt by phosphorylating its serine threonine residues 
(Kohn et al. 1995), which can be blocked by PDK inhibitors (Franke et al. 1995; Kohn et 
al. 1996b). In cell culture experiments, it was shown that constitutively active Aktl may 
promote Glut4 translocation with no insulin stimulation (Kohn et al. 1996a). Mice 
knockout studies also revealed the importance of Akt molecules in insulin signal 
transduction. Although Aktl knockout mice do not show a diabetic phenotype, Akt2 
knockout mice have increased blood glucose and insulin levels, hepatic insulin resistance 
and modest muscle insulin resistance (Cho et al. 2001a; Cho et al. 2001b). Although the 
link between Akt activation and Glut4 translocation remains to be determined, a Rab-
GAP containing Akt substrate could possibly be important since this protein family is 
important in membrane trafficking (Kane et al. 2002) (Zerial and McBride 2001). The 
role of other PDK substrates such as atypical protein kinase C (PKC), PKCX, £ or 6, still 
remains to be determined (Braiman et al. 1999; Standaert et al. 1999). 
Mechanisms for fatty acid induced insulin resistance 
Insulin and Nutrient Sensing 
The epidemic increases in obesity and type II diabetes draw a lot of attention to 
nutrient sensing pathways and to the regulation of food intake and energy expenditure. It 
is evident that increased food intake and weight gain is correlated with insulin resistance. 
In addition to increasing glucose uptake into insulin sensitive tissues and inhibiting 
hepatic glucose output, insulin also exerts other metabolic effects on several tissues. 
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Before the cloning of the adipocyte hormone leptin, insulin was suggested to be 
the peripheral hormone, which can relay information about the peripheral energy stores to 
the CNS. First of all, there is a correlation between adiposity and plasma insulin levels 
(Woods et al. 1998). Furthermore, plasma insulin levels correlate well with acute energy 
status, in the order of minutes to hours. During a positive energy balance, there is a 
subsequent increase in plasma insulin levels, which decreases with a negative energy 
balance such as fasting (Benoit et al. 2004). Insulin is very important in both glucose and 
lipid usage as well as glucose storage by peripheral tissues. In insulin resistant states, 
plasma insulin levels increase which result in increased fat accumulation in adipocytes. 
Secondly, when insulin is administered into the brain, this decreases food intake while 
increasing energy expenditure (Woods et al. 1996b; Air et al. 2002). Peripheral 
administration of insulin was also shown to decrease food intake (Nicolaidis and 
Rowland 1976; VanderWeele et al. 1982). Furthermore, when insulin antibodies were 
infused in rat brains, these animals ate more and gained weight (McGowan et al. 1992). 
Insulin is suggested to act through its receptors in the arcuate nucleus of the 
hypothalamus in order to exert its effects on food intake and energy expenditure (Benoit 
et al. 2004). When insulin was injected into the third ventricle, there was a decrease in 
neuropeptide Y (NPY) expression (Schwartz et al. 1992; Sipols et al. 1995), and an 
increase in corticotrophin (ACTH)-releasing hormone expression (Sipols et al. 1995; 
Schwartz et al. 1996). 
Central insulin action was also shown to affect peripheral insulin sensitivity. 
When insulin receptor was knocked out specifically in the brain, these mice developed 
mild insulin resistance as well as hypertriglyceridemia. These mice also showed 
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increased food intake and adiposity (Bruning et al. 2000). In other studies where insulin 
receptor was downregulated in the arcuate nucleus of rats using antisense 
oligonucleotides, these animals became hyperphagic and gained weight (Obici et al. 
2002a). Under hyperinsulinemic-euglycemic clamp conditions, these animals showed 
impaired hepatic insulin sensitivity with a reduced response to insulin-mediated 
suppression of gluconeogenesis (Obici et al. 2002c). 
Nutrient sensing is crucial in body weight homeostasis and insulin sensitivity. 
Increased body weight is strongly associated with insulin resistance. One pathway by 
which the organism senses nutrient fluxes is by malonyl coenzyme A (CoA)/long chain 
fatty acid (LCFA)-CoA pathway (Obici and Rossetti 2003). Malonyl CoA was initially 
suggested to be a fuel sensor that operates as a switch between fatty acid oxidation and 
glucose oxidation (McGarry et al. 1977). In the presence of high levels of glucose and 
insulin, malonyl CoA levels increase which act as a negative inhibitor of carnitine 
palmitoyltranferase (CPT)l. CPT1 is the rate-limiting enzyme for fatty acid oxidation. 
This is the transporter for LCFA-CoAs into the mitochondria where fatty acid oxidation 
takes place. This way when glucose is available, the cell favors glucose oxidation in 
place of fatty acid oxidation and lipid is stored as triglycerides in order to be used in the 
absence of glucose (Obici and Rossetti 2003). 
In addition to cellular nutrient sensing in the peripheral tissues, it was recently 
shown that hypothalamic neurons may also be important in nutrient sensing. When oleic 
acid, a LCFA-CoA, was administered directly into the brain, there was a decrease in food 
intake and glucose production (Obici et al. 2002b). This suggests that LCFA-CoAs may 
act in the hypothalamus to signal increased nutrient availability thus inhibiting excess 
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nutrient intake and glucose production. This was also supported by studies where CPT1 
expression was inhibited in the hypothalamus. In these studies, there was also a decrease 
in food intake and glucose production (Obici et al. 2003). 
Insulin resistance and fatty acid metabolism 
Nutrient sensing pathways are crucial for body weight and energy homeostasis 
and changes in these pathways might lead to an increase in adiposity and insulin 
resistance. There is a positive correlation between body fat content, diabetes and insulin 
resistance (Colditz et al. 1990). It is also suggested that regional fat depots are better 
indicators of diabetes and insulin resistance. For example, intra-abdominal fat depots are 
much better indicators of diabetes compared to subcutaneous fat depots (Kissebah and 
Krakower 1994). 
A number of different mechanisms are implicated in the pathogenesis of insulin 
resistance and diabetes associated with obesity. One of these mechanisms is reduced 
insulin signaling in obesity due to increased phosphatase activity Phosphatases 
dephosphorylate insulin signaling molecules hence impairing insulin signal transduction 
as well as the following insulin mediated events. In obese humans and rodents, there is 
an increase in protein tyrosine phosphatase (PTP) expression and/or activity (Goldstein et 
al. 1998). Furthermore, PTPlb knockout mice have increased energy expenditure, are 
resistant to diet-induced obesity and show increased insulin sensitivity in muscle and 
liver (Elchebly et al. 1999; Klaman et al. 2000). 
A second mechanism is the role of fatty acids which accumulate ectopically in 
peripheral tissues such as liver, muscle and P-cells that cause an impairment of insulin 
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signaling and hence insulin resistance in these tissues. In humans, a strong correlation 
has been shown between insulin resistance and increased circulating triglycerides and 
free fatty acids as well as increased intracellular fat in several tissues (Schalch and Kipnis 
1965; Reaven 1995; McGarry 2002). A number of studies in both rodents and humans 
showed that whole-body insulin sensitivity is inversely proportional to muscle 
triglyceride content (McGarry 2002). A number of studies reported that intramyocellular 
lipid (IMCL) has a very strong positive correlation with insulin resistance (Forouhi et al. 
1999; Krssak et al. 1999; Perseghin et al. 1999; Levin et al. 2001). Furthermore, when 
healthy individuals were infused with heparin/lipid over a period of several hours under 
hyperinsulinemic-euglycemic clamp conditions, insulin-mediated muscle glucose uptake 
was significantly suppressed (Boden et al. 1995; Roden et al. 1996; Brechtel et al. 2001). 
One of these studies showed that opposite to Randle's hypothesis, there was a 
decrease in glucose-6-phosphate levels in the muscle following lipid infusion (Roden et 
al. 1996). This observation suggested that fatty acids impaired insulin sensitivity in 
muscle either through impaired glucose uptake or phosphorylation. Randle and his 
colleagues performed a number of studies about 40 years ago, which lead to their 
proposal of the fatty acid-glucose cycle. These studies showed that in isolated rat heart 
muscle and rat diaphragm muscle, there was a competition between glucose and fatty 
acid oxidation and further speculated that fatty acid oxidation leads to obesity associated 
insulin resistance (Randle et al. 1963; Randle et al. 1964; Randle et al. 1965). Randle 
proposed that with elevated intramyocellular fatty acids, ratios of intramitochondrial 
acetyl CoA/CoA and NADH/NAD+ both increased. These increases in turn inactivate 
pyruvate dehydrogenase and increase citrate levels. Increased citrate in turn inactivates 
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phosphofrucktokinase, which in turn would increase glucose-6-phosphate levels in the 
cells. This would in turn inhibit hexokinase II activity hence causing glucose to 
accumulate in the cell and eventually inhibiting glucose uptake (Shulman 2000). Studies 
by Shulman and colleagues however, suggest that this mechanism is not entirely accurate. 
In a number of studies, they have shown that increased fatty acyl CoAs, diacylglycerol 
and ceramides activate protein kinase C 6 (PKC9), which in turn activates a 
serine/threonine kinase cascade. Activation of this cascade increases serine/threonine 
phosphorylation of IRS-1 and IRS-2 molecules and hence decreases insulin-stimulated 
tyrosine phosphorylation. This results in a subsequent insensitivity to insulin in the cell, 
where PI 3 kinase activity and Glut4 translocation to the cell membrane decreases as well 
as a subsequent decrease in glucose uptake (Rothman et al. 1992; Petersen et al. 1998; 
Dresner et al. 1999; Griffin et al. 1999). 
Other mediators of insulin resistance 
There are several possible reasons for lipid accumulation in peripheral tissues. 
One of these reasons might be failure of new fat cell formation. Adipocytes from insulin 
resistant individuals are larger and suggest that there might be defects in adipocyte 
differentiation and proliferation (Ravussin and Smith 2002). A second reason might be 
an impairment in fatty acid oxidation, which in turn leads to intracellular fat 
accumulation. It is possible that fatty acid oxidation may not be able to keep up with 
increased food intake or there might be a defect in fatty acid oxidation which in turn 
would increase intracellular lipid accumulation (Ravussin and Smith 2002). A third 
reason might be due to defective regulation of one or more of several adipocyte-secreted 
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factors. Adipose tissue is now considered an endocrine organ. It secretes several 
hormones and factors that are important in glucose homeostasis. These factors include 
leptin, adiponectin, TNF-a, IL-6 and resistin. Several of these factors have been 
associated with insulin resistance (Pittas et al. 2004). 
Lately, adiponectin has been increasingly associated with insulin resistance. 
Unlike other adipocytokines, obese and diabetic rodents and humans have reduced 
adiponectin mRNA and protein levels (Hu et al. 1996; Statnick et al. 2000). Adiponectin 
treatment partially improves hyperglycemia and hyperinsulinemia associated with 
lipoatrophy and obesity in rodents. When lipoatrophic mice were simultaneously treated 
with adiponectin and leptin, insulin resistance was completely corrected (Yamauchi et al. 
2001). Furthermore, adiponectin overexpressing ob/ob mice have improved insulin 
sensitivity (Yamauchi et al. 2003). Adiponectin knockout mice on the other hand have 
moderate insulin resistance and glucose intolerance (Kubota et al. 2002). Adiponectin 
was also shown to increase hepatic insulin action and thus improve glucose homeostasis 
(Berg et al. 2001). More recently, adiponection was also shown to act in the brain to 
exert its effects on body weight and glucose homeostasis by activating energy 
expenditure (Qi et al. 2004). 
Resistin is another polypeptide secreted by adipose tissue. In both ob/ob and 
db/db mice, resistin levels are elevated (Steppan and Lazar 2002). When resistin is 
administered to wild type mice, this has adverse effects on insulin sensitivity whereas 
when resistin is immunoneutralized in insulin resistant mice, their insulin sensitivity 
improves (Steppan et al. 2001). Recently, resistin was suggested to inhibit insulin 
mediated suppression of hepatic glucose output (Rajala et al. 2003). 
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TNF-a is a proinflammatory cytokine, which is also elevated in obese and insulin 
resistant animals and humans (Fried et al. 1998). In obese rats, immunoneutralization of 
TNF-a improved their insulin sensitivity (Hotamisligil et al. 1993), however, in humans 
these results have not yet been confirmed (Ofei et al. 1996). IL-6 is another cytokine, 
whose levels are elevated in obesity and insulin resistance (Kern et al. 2001; Vozarova et 
al. 2001). When IL-6 was administered to healthy individuals, blood glucose levels were 
elevated in these individuals (Tsigos et al. 1997). 
Leptin is the most intensely studied adipocyte hormone, which has several 
metabolic effects and was shown to be important in insulin sensitivity. The metabolic 
effects of leptin are discussed in more detail in the section below. Other factors such as 
glucocorticoids, growth factors, IGF-1 and sex steroids might be important factors that 
modulate adipocyte size and have an effect on glucose homeostasis (Ravussin and Smith 
2002). 
Leptin's Metabolic Effects 
Leptin as a satiety hormone 
Kennedy proposed the lipostatic hypothesis which stated that circulating factors 
from body fat depots act on the brain in order to control body fat mass by changing food 
intake and energy expenditure (Kennedy 1953). Later in 1970s, Coleman's parabiosis 
experiments, which used two monogenic rodent forms of obesity and insulin resistance, 
ob/ob mice and db/db mice as well as lean mice, suggested the presence of a factor in 
db/db mice which was missing in the ob/ob mice and the receptor for this factor was 
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missing in db/db mice but was present in ob/ob mice (Coleman 1973). About 30 years 
after these observations, Dr. Friedman and his colleagues cloned the ob gene, leptin, and 
subsequently shortly after, leptin receptor, ObR, was also cloned (Zhang et al. 1994; 
Tartaglia etal. 1995). 
Leptin is mainly expressed by white adipose tissue. It is a 146 amino acid and 
16kDa hormone that regulates energy balance (Friedman and Halaas 1998; Schwartz et 
al. 2000; Bjorbaek and Kahn 2004). Ob/ob mice has a mutation in the leptin gene and 
hence make a defective protein that does not get secreted (Zhang et al. 1994). 
Administration of leptin into ob/ob mice, which are obese, diabetic, sterile with decreased 
energy expenditure, body temperature and activity, was able to correct these metabolic 
abnormalities (Campfield et al. 1995; Halaas et al. 1995; Pelleymounter et al. 1995). In 
contrast to ob/ob mice, which make no leptin, it was shown in both humans and animals 
that there is a direct correlation between plasma leptin levels and body fat content. Obese 
individuals and animals have higher plasma leptin levels compared their lean 
counterparts (Frederich et al. 1995; Maffei et al. 1995). Leptin has been shown to have a 
number of direct and indirect effects on food intake, energy expenditure as well as other 
metabolic functions such as glucose and fat metabolism, reproductive function and 
immune function (Friedman and Halaas 1998; Baile et al. 2000). 
Leptin receptors belong to the class I cytokine receptor family. This receptor 
family acts through janus activating kinase-signal transducer and activator of 
transcription (JAK-STAT) signaling pathway. Leptin receptors are expressed on several 
peripheral tissues such as liver, muscle, pancreatic p-cells and adipose tissue as well as in 
chroid plexus and hypothalamus. There are 5 splice variants of the ob receptor gene, 
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ObRa-e with various C-terminal lengths (Lee et al. 1996). ObRb is the long form of the 
leptin receptor which contains the full cytoplasmic tail and is thought to be the only form 
that can signal, db/db mice have a mutation in the leptin receptor gene, which replaces 
ObRb isoform with ObRa isoform, which lacks the full cytoplasmic tail, and these 
animals do not respond to leptin (Chen et al. 1996). The shorter forms of leptin receptor 
might be important for leptin binding such as the soluble ObRe form (Lee et al. 1996; Li 
et al. 1998) or for leptin transport across the blood-brain barrier such as the ObRa isoform 
that is highly expressed in choroid plexus and brain microvessels (Fei et al. 1997; 
Bjorbaek et al. 1998). 
Initial studies of leptin focused on the central action of leptin to control food 
intake and energy expenditure. When leptin was administered directly into the brain in 
rodents, it was shown to reduce food intake and body weight (Campfield et al. 1995; 
Stephens et al. 1995). More recently, mice with a brain specific knockout of the leptin 
receptor were generated, which have an obese phenotype further supporting the 
importance of CNS in leptin's effect on body weight control (Cohen et al. 2001). 
Hypothalamus has specific nuclei where ObRb isoform of the leptin receptor is highly 
expressed; these regions include arcuate, dorsomedial, ventromedial and ventral 
premammary nuclei. Other regions such as periventricular hypothalamic nucleus, lateral 
hypothalamic area and paraventricular nucleus also express this receptor albeit at lower 
levels (Mercer et al. 1996; Fei et al. 1997; Elmquist et al. 1998). These hypothalamic 
nuclei were shown to express several neuropeptides that are important regulators of 
leptin's effects on food intake and energy homeostasis (Friedman 2002b). These 
neuropeptides include the anorectic peptides such as alpha melanocyte-stimulating 
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hormone (a-MSH) secreted by P O M C neurons in the arcuate nucleus and cocaine and 
amphetamine-regulated transcript (CART); both of these neuropeptides are activated by 
leptin. Orexigenic peptides such as melanocortin receptor antagonist agouti-related 
protein (AgRP) and neuropeptide Y (NPY), on the other hand, are inhibited by leptin 
(Schwartz et al. 2000; Friedman 2002b). 
Leptin and Energy Metabolism 
In addition to its effects on food intake and body weight regulation via the CNS, 
leptin was also shown to have a number of metabolic effects on lipid and glucose 
metabolisms in peripheral tissues indirectly via the CNS and directly on some other 
tissues. There is evidence suggesting that leptin's metabolic effects are independent of its 
effect on food intake (Friedman 2002b). Food restriction causes a decrease in both lean 
and fat body mass whereas leptin treatment is selective for fat mass reduction (Halaas et 
al. 1995; Levin et al. 1996; Halaas et al. 1997). Moreover, food restriction causes a 
reduction in energy expenditure whereas energy expenditure does not decrease with 
leptin treatment (Halaas et al. 1997). The reason for this might be that leptin treatment 
increases uncoupling protein (UCP). There is data suggesting that UCP-1 and UCP-2 
expression increases in WAT and BAT and UCP-3 expression increases in BAT and 
muscle following subcutaneous leptin treatment in both leptin deficient ob/ob mice and in 
wild type mice (Sarmiento et al. 1997; Scarpace and Matheny 1998; Commins et al. 
1999). 
Central leptin treatment also causes an increase in UCP-1 expression suggesting 
that leptin mediates its actions via the sympathetic nervous system (SNS) acting on beta3 
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adrenergic receptors (P3AR) on peripheral tissues (Collins et al. 1996). There are three 
beta-adrenergic receptors. P3AR knockout mice do not have an obesity phenotype 
presumably due to compensation from the other two adrenergic receptors (Susulic et al. 
1995). However, when all three beta adrenergic receptors were knocked out in mice, 
these animals were slightly obese on a chow diet but they developed diet induced obesity 
suggesting the importance of beta adrenergic activity in diet induced thermogenesis 
(Bachman et al. 2002). 
Leptin and Lipid Metabolism 
In addition to decreasing triacylglycerol storage in adipose tissue and hence 
decreasing adipose tissue mass and changing gene expression in this adipose tissue 
(Soukas et al. 2000), leptin has unique effects on lipid metabolism in nonadipose tissues 
such as liver, muscle, heart and pancreatic p-cells. This effect of leptin is very important 
in peripheral insulin sensitivity. 
In obesity, where there is too 
much adipose mass and in lipodystrophy, 
where there is not enough adipose mass, 
lipids accumulate in peripheral tissues 
such as liver, muscle, heart and 
pancreatic p-cells and this accumulation 
is suggested to have a "toxic" effect on 
these tissues. Leptin is suggested to have 
a protective role against this "lipotoxicity" 
Figure 1.3 Hepatic Steatosis , reduction of W.4T 
and undifferentiated BAT in aP2-nSREBP-lc 
transgnic mice (Taken from Shimomura et al. 
1998) 
(Friedman 2002a; Unger 2003). This role of 
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leptin in lipid metabolism is perhaps most evident in ob/ob or db/db mice where in the 
absence of the leptin or its receptors, in addition to increased body fat mass, there is 
increased accumulation of triglycerides in peripheral tissues such as muscle, heart, 
pancreatic P-cells and liver which results in the enlarged fatty livers in these mice (Lee et 
al. 2001). Hepatic steatosis is also evident in leptin deficient lipodystrophic mice, which 
lack adipose tissue (Shimomura et al. 1998) (Figure 1.3). 
Hepatic steatosis is a disease, which is highly associated with obesity and insulin 
resistance. This condition is caused by the accumulation of triglycerides into hepatocytes 
which might be caused by a number of defects. Hepatic steatosis may progress via 
steatohepatitis to fibrosis and cirrhosis of the liver, which might be fatal (Clark and Diehl 
2002). Nonalcoholic fatty liver disease (NAFLD) is the general name given to all of 
these liver conditions and this disease affects about 30 million people in the United States 
of America (Browning and Horton 2004). 
Although the exact mechanisms by which leptin exerts its antisteatotic effects are 
still under investigation, a number of studies suggest that leptin increases fatty acid 
oxidation and blocks fatty acid synthesis (lipogenesis) in peripheral tissues. In studies 
where cultured pancreatic islets were used, leptin decreased triglyceride synthesis and 
increased fatty acid oxidation hence decreasing triglyceride content of these cells 
(Shimabukuro et al. 1997). Normal rats treated with a leptin adenovirus also had 
decreased triglyceride content in tissues such as liver, muscle and pancreas with no 
increase in plasma ketones or free fatty acids (Shimabukuro et al. 1997). 
In another study, leptin was shown to act via PPARa in order to exert its effects 
on fatty acid oxidation. PPARa knockout mice treated with a leptin adenovirus lost less 
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adipose tissue with no change in liver triacylglycerol compared to leptin treated wild-type 
mice (Lee et al. 2002). Another study suggested that, leptin was able to activate fatty 
acid oxidation and decrease triglyceride content of isolated rat hearts (Atkinson et al. 
2002). Another mechanism by which leptin prevents lipotoxicity is via activating AMP-
activated protein kinase (AMPK) (Chehab et al. 2004). In one study, leptin was shown to 
phosphorylate and activate AMPK in muscle directly and indirectly via the CNS 
(Minokoshi et al. 2002). AMPK is suggested to be a "fuel sensor" in cells (Hardie and 
Carling 1997). AMPK phosphorylates and inactivates acetyl-coA carboxylase (ACC) 
and activates malonyl CoA decarboxylase (MCD). Both of these has an end result of 
lowering malony CoA levels which in turn releases the inhibition on the mitochondrial 
fatty acid transporter carnitine palmitoyl transferase 1 (CPT-1) (McGarry et al. 1977; 
McGarry 2002). This leads to increased fatty acid import into the mitochondria where 
fatty acid oxidation takes place (Winder and Hardie 1999). In one study, where rats were 
treated with subcutaneous leptin, both AMPK expression and phosphorylation and ACC 
phosphorylation in soleus and gastrocnemius muscles were increased (Steinberg et al. 
2003). These data are in accordance with the ACC2 knockout mice which have increased 
fatty acid oxidation and decreased adiposity (Abu-Elheiga et al. 2001). Moreover, these 
mice are resistant to diet induced obesity and diabetes (Abu-Elheiga et al. 2003). 
Another important enzyme in leptin mediated fatty acid oxidation is stearoyl-CoA 
desaturase-1 (SCD-1) (Cohen et al. 2002). This is a rate-limiting enzyme in the 
triglyceride synthesis pathway and it generates monounsaturated fatty acids from 
saturated fatty acids (Ntambi and Miyazaki 2003). This enzyme is upregulated in the 
livers of leptin-deficient ob/ob mice and leptin downregulates its expression and activity. 
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When asebia mice, a natural knockout for SCD-1 gene, were crossed to ob/ob mice, these 
mice had reduced body mass, increased metabolic rate and improved hepatic steatosis 
(Cohen et al. 2002). Similarly, SCD-1 knockout mice were leaner and resistant to diet 
induced obesity compared to their littermate controls. They also had increased metabolic 
rate and increased muscle insulin sensitivity (Ntambi et al. 2002; Rahman et al. 2003). 
Leptin and Carbohydrate Metabolism 
Leptin has unique effects on glucose metabolism that are independent of its 
effects on food intake and body fat reduction. Initially, leptin was shown to correct 
hyperinsulinemia and hyperglycemia associated with ob/ob mice even at doses that has 
no effect on body weight (Pelleymounter et al. 1995). Leptin corrected both hepatic 
steatosis and insulin resistance in aP2-nSREBP-lc lipodystrophic mice whereas food 
restriction had no effect on insulin resistance even though it improved hepatic steatosis 
(Shimomura et al. 1999). In insulin-deficient rats, leptin also normalized glucose levels 
and glucose turnover (Chinookoswong et al. 1999). Moreover, mice which overexpress 
leptin were shown to have improved insulin sensitivity (Ogawa et al. 1999; Qiu et al. 
2001). 
Several studies suggest that leptin acts on pancreatic p-cells affecting insulin 
secretion but it should be noted that there are conflicting results regarding these effects 
(Kieffer and Habener 2000). Many of these studies suggest that leptin inhibits insulin 
secretion. When pancreatic islets from ob/ob mice were incubated with leptin or when 
pancreas from ob/ob mice was perfused with leptin, both of these treatments inhibited 
insulin secretion (Emilsson et al. 1997; Kieffer et al. 1997). In these studies, leptin is 
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suggested to act via the ATP-dependent K+ (KAtp) channels, hyperpolarizing and hence 
opening and activating these channels and inhibiting voltage-dependent Ca channels, 
thus inhibiting insulin secretion (Kieffer et al. 1997). Several studies also suggest that 
leptin suppresses preproinsulin gene expression in pancreatic P-cells (Kulkarni et al. 
1997; Seufert et al. 1999). 
Several other reports also suggest that insulin can change leptin gene expression 
and secretion. In rats, it was shown that leptin gene expression has diurnal regulation, 
expression levels increasing at night when rats are feeding and plasma insulin levels are 
high. Food deprivation inhibits leptin gene expression, which may be restored with 
refeeding as well as with insulin administration in the fasted state (Saladin et al. 1995). 
In insulin-deficient rats, insulin treatment but not food restriction increases leptin gene 
expression. 
In a number of acute leptin treatment studies, leptin was shown to have effects on 
gluconeogenesis and hepatic glycogen synthesis. In wild-type mice, both central and 
peripheral leptin administration were shown to stimulate whole-body glucose turnover, 
causing increased muscle and brown fat glucose uptake, a decrease in liver glycogen 
content and an increase in glycolysis (Kamohara et al. 1997). In other studies, both 
central and peripheral leptin treatments were shown to inhibit hepatic glycogenolysis 
while increasing gluconeogenesis through PEPCK activation, therefore promoting fatty 
acid oxidation. In these studies, leptin had no effect on insulin-stimulated glucose 
clearance or glycolysis (Rossetti et al. 1997; Liu et al. 1998). In ob/ob mice on the other 
hand, leptin was shown to decrease PEPCK expression in liver whereas glucose-6-
phosphatase activity and hepatic glucose output were increased. Glucose turnover and 
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glucose uptake in several tissues such as brain, B A T and heart were also increased 
(Burcelin et al. 1999). 
In other studies, where leptin was administered for a long period rather than 
acutely, leptin's effects were rather different. In one such study where rats were treated 
with subcutaneous leptin for eight days, there was a decrease in adiposity and increase in 
insulin sensitivity compared to food-restricted rats. In liver of these animals, leptin 
decreased hepatic glucose production by inhibiting glycogenolysis even though PEPCK 
expression and gluconeogenesis were induced. In these rats, there was an increase in 
whole-body and liver glycogen synthesis as well as an increase in hepatic glycolysis 
(Barzilai et al. 1997). In another study in rats, chronic leptin treatment also increased 
glycolysis, PEPCK expression and gluconeogenesis (Barzilai et al. 1999). Both acute 
and chronic leptin were also shown to increase hepatic glycogen synthesis in both ob/ob 
and wild type mice using 13C NMR spectroscopy (Cohen et al. 1998). 
Even though there is evidence from cell culture experiments showing that leptin 
can directly act on and hence effect carbohydrate and lipid metabolism in hepatocytes 
(Cohen et al. 1996; Wang et al. 1997), mice with a liver-specific knockout of the leptin 
receptor are normal with no abnormalities in lipid or glucose metabolism whereas brain-
specific knockout of the leptin receptor are obese, diabetic and have hepatic steatosis 
(Cohen et al. 2001) suggesting that leptin acts via the CNS to exert its actions on liver. 
For a long time, too much fat was considered to be bad for both lipid and glucose 
metabolisms, however, the importance of adipose tissue was once again understood when 
lipodystrophic mice and humans were studied. These studies suggested that too much fat 
is definitely bad however, too little fat and specially in the wrong places is similarly bad 
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(Friedman 2002a). Leptin was shown to improve insulin resistance and hepatic steatosis 
in a number of lipodystrophic mouse models such as A-ZIP/F1 mice, aP2-nSREBP-lc 
transgenic mice and IRS-l/IRS-3 double knockout mice (Shimomura et al. 1999; Ebihara 
et al. 2001; Laustsen et al. 2002). Crossing leptin overexpressing mice to the 
lipodystrophic A-ZIP/F1 mice was able to correct insulin resistance in these 
lipodystrophic animals (Ebihara et al. 2001). Furthermore, adipose tissue transplantation 
from wildtype mice but not from ob/ob mice corrects insulin resistance in A-ZIP/F1 mice 
(Gavrilova et al. 2000; Colombo et al. 2002). Similar effects of leptin treatment were 
also shown in lipodystrophic humans (Oral et al. 2002; Petersen et al. 2002). 
Role of leptin in glucose homeostasis in humans 
Mutations identified in human diabetes and insulin resistance 
Type II diabetes is a complex disorder where both insulin sensitivity and p-cell 
function are impaired. Obesity and type II diabetes are closely associated, more than 
85% of type II diabetics are also obese (O'Rahilly 2002). Type II diabetes is a complex 
disorder where genetic factors interact with each other and with environmental factors to 
manifest the disease. Rare single gene mutations that cause defects in p-cell function and 
hence cause early onset diabetes have been identified in humans. Some of these single 
gene mutations cause early onset diabetes called maturity onset diabetes of the young 
(MODY). Mutations in glucokinase gene cause MODY2 (Stoffel et al. 1992a; Stoffel et 
al. 1992b; Vionnet et al. 1992). It was later shown that mutations in hepatocyte nuclear 
factor-4alpha gene cause MODY1 (Yamagata et al. 1996). Mutations in hepatocyte 
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nuclear factor-1 alpha cause M O D Y 3 , insulin promoter factor-1 mutations cause M O D Y 4 
and hepatocyte nuclear factor-lbeta mutations cause MODY5 (Shih and Stoffel 2002). 
Mutations in insulin receptor gene were also shown to cause extreme insulin 
resistance syndromes in humans such as Donahue's syndrome, Rabson-Mendenhall 
syndrome and Type A insulin resistance. Individuals with these mutations usually do not 
have major developmental defects, however, they have severe insulin resistance, 
acathosis nigricans, hyperandrogenization and women usually also have polycystic 
ovarian disease (Kahn et al. 1996). 
Individuals with severe hyperinsulinaemia were also found to have mutations in 
PPARy gene, which is an important regulator of lipogenesis and insulin sensitivity, as 
well as in PPPIR3 A gene which encodes for the regulatory subunit of phosphatase 1. 
This enzyme is important in glycogen synthesis in striated muscle (O'Rahilly 2002). 
Lipoatrophy and lipodystrophy syndromes are also associated with severe insulin 
resistance. Lipoatrophy is the characteristic loss of fat and lipodystrophy is the selective 
loss and abnormal distribution of fat. These syndromes are associated with diabetes, 
dyslipidemia, hepatic steatosis and acanthosis nigricans as well as polycystic ovary 
syndrome in women (Oral 2003; Garg 2004). There are two types of lipodystrophies, 
acquired form and inherited form. Inherited form of lipodystrophy include type 1 and 
type 2 congenital generalized lipodystrophy. Type 1 congenital generalized 
lipodystrophy is an autosomal recessive disease, caused by mutations in the 1-
acylglycerol-3-phosphate o-acyltransferase (AGPAT)2 gene. This enzyme is expressed 
in adipose tissue and is involved in triglyceride and phospholipid synthesis. Mutations in 
this enzyme might cause decreased triglyceride and phosholipid synthesis in adipocytes 
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and hence cause the extreme lack of adiposity observed in the affected individuals since 
birth. Type 2 congenital generalized lipodystrophy is also an autosomal recessive disease 
caused by mutations in the seipin gene. The function of this gene is unknown and 
individuals who have mutations in this gene have extreme lack of adiposity since birth as 
well as mild mental retardation and cardiomyopathy. A second form of inherited 
lipodystrophy is called Familial partial lipodystrophy. There are two types of this form, 
the first type is called Dunnigan variety and is caused by autosomal dominant mutations 
in LMNA gene. LMNA gene encodes for nuclear lamina proteins lamin A and C. The 
exact mechanism by which these mutations cause lipodystrophy is not known but these 
mutations might cause adipocyte apoptosis. Individuals with these mutations have 
selective loss of subcutaneous adipose tissue at puberty from their arms, legs and trunk. 
The second type of familial partial lipodystrophy is caused by autosomal dominant 
mutations in peroxisome-proliferator-activated receptory (PPARy) gene. This gene 
encodes for a transcription factor crucial in adipocyte differentiation and dominant 
negative mutations in this gene might inhibit adipocyte differentiation. Individuals with 
these mutations loose subcutaneous fat from their arms, legs and face. The third type of 
inherited lipodystrophy is mandibuloacral dysplasia, which has two types, type A and 
type B. Type A lipodystrophy is an autosomal recessive mutation in LMNA gene. These 
individuals have skeletal anomalies as well as subcutaneous fat loss from their arms, legs 
and trunk. Type B lipodystrophy is an autosomal recessive mutation in ZMPSTE24 
gene. This gene encodes for zinc metalloproteinase, which is important for lamin A 
protein processing from prelamin A protein. These individuals also have skeletal 
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anomalies as well as a generalized fat loss, premature renal failure and progeroid features 
(Garg 2004). 
Acquired lipodystrophy is associated with HIV patients that are being treated with 
the highly active antiretroviral therapy (HAART) of protease inhibitors. The mechanism 
by which these drugs cause lipodystrophy is not known but they might be inhibiting 
adipocyte differentiation or causing adipocyte apoptosis. Other acquired forms of 
lipodystrophy include acquired partial or acquired generalized lipodystrophy, which 
might be caused by an autoimmune attack on adipose tissue. A localized acquired 
lipodystrophy is also seen in some patients and a number of mechanisms might be 
involved (Garg 2004). 
Role of leptin in the pathogenesis of diabetes 
So far, leptin was shown to be efficient in treating two rare human conditions, one 
of these is obesity associated with leptin deficiency and the other is lipodystrophy 
associated with very low leptin levels (Gorden and Gavrilova 2003). Initially, leptin was 
shown to correct insulin resistance, hyperinsulinemia and hyperglycemia in ob/ob mice in 
addition to reducing food intake and body weight while increasing energy expenditure in 
these animals (Campfield et al. 1995; Halaas et al. 1995; Pelleymounter et al. 1995). 
Secondly, leptin was shown to correct metabolic abnormalities including insulin 
resistance, hyperglycemia, hyperinsulinemia and hepatic steatosis associated with aP2-
nSREBP-lc transgenic mice, which is a rodent form of congenital lipodystrophy. These 
mice express a truncated version of the transcription factor sterol regulatory element-
binding protein lc (SREBP-lc), which stays in the nucleus and is constitutively active 
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(Shimomura et al. 1998; Shimomura et al. 1999). Later, leptin was also shown to correct 
insulin resistance and hepatic steatosis associated with another form of lipoatrophy. A-
ZIP/F-1 mice, which was generated by expressing a dominant negative protein to A-ZIP 
transcription factor (Moitra et al. 1998; Ebihara et al. 2001). Furthermore, in these mice 
transplanting adipose tissue from wild-type mice, but not from leptin-deficient ob/ob 
mice, corrected insulin resistance (Gavrilova et al. 2000; Colombo et al. 2002). More 
recently, leptin was also shown to correct the metabolic abnormalities including insulin 
resistance in two other models of lipoatrophy (Yamauchi et al. 2001; Laustsen et al. 
2002). Leptin's effects in both ob/ob and lipodystrophic mice are not due merely of its 
effects on food intake. Food restriction in these animal models causes reduction in body 
weight and improvement in hepatic steatosis but does not improve insulin resistance 
(Shimomura et al. 1999; Ebihara et al. 2001). 
Similar to its effects in mouse models of lipodystrophy, leptin was also shown to 
improve hyperglycemia, hyperinsulinemia, insulin resistance, hypertriglyceridemia and 
hepatic steatosis in human lipodystrophic patients (Oral et al. 2002; Petersen et al. 2002). 
Euglycemic-hyperinsulinemic clamp studies of leptin treated lipodystrophic patients 
showed that leptin increased insulin sensitivity in these patients as well as lowering 
blood, liver and muscle triglyceride content (Petersen et al. 2002). 
Recently, recombinant methionyl human leptin therapy was also shown to 
improve severe insulin resistance, hyperglycemia, hyperinsulinemia as well as glucose 
and insulin tolerance in two patients with Rabson-Mendenhall Syndrome. These patients 
presumably had insulin receptor mutations with extreme insulin resistance and low serum 
triglyceride levels (Cochran et al. 2004). 
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Molecular targets for glucose homeostasis regulation 
Current and future treatments for diabetes 
The increasing epidemic of type II diabetes is becoming a huge burden on the 
healthcare systems worldwide therefore, prevention and efficient treatments of this 
disease are extremely important. Currently, the first suggested treatment for type II 
diabetics is diet and exercise however, if and when these fail to control blood glucose 
levels, there are five classes of oral antidiabetic drugs that may be used. These drugs 
include metformin, a biguanide, which might activate jAMPK and hence suppress hepatic 
glucose output and increase muscle glucose uptake (Zhou et al. 2001), pioglitazone and 
rosiglitazone, which are thiazolinidinediones that act through activating PPARy, a-
glucosidase inhibitors which act by delaying intestinal carbohdydrate absorption and 
finally sulfonylureas (SU) and non-sulfonlyurea (non-SU) that stimulate pancreatic P-cell 
insulin secretion. In more severe forms of diabetes, insulin is also prescribed (Ross et al. 
2004). Besides these drugs, which are currently being used, there are a number of other 
drug targets that are currently under trials. These include, insulin receptor mimetics, 
PTP IB inhibitors, adiponectin, inhibitors for IKKp and JNK1 and AMPK activators 
(Ross et al. 2004). However, none of the available therapies can prevent or treat all of the 
different aspects of this disease. Therefore, it is of great interest to understand the exact 
molecular mechanisms that underlie insulin resistance in order to be able to prevent the 
development of type II diabetes and also to identify better drug targets for treatment. 
Since, the recent obesity and diabetes epidemics are linked, it is important to understand 
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the molecular mechanisms underlying insulin resistance that is associated with obesity 
and other lipid disorders. 
Specific Aims 
This thesis aims to further elucidate the molecular mechanisms of leptin's 
antidiabetic effects. The site of leptin's antidiabetic effects was studied by peripheral and 
central administrations of leptin into lipodystrophic aP2-nSREBP-lc transgenic mice, 
which are insulin resistant (Chapter 3). These studies showed that leptin acts via the 
central nervous system in order to correct insulin resistance in these mice. Furthermore, 
we showed that leptin also acts via the CNS to regulate liver gene expression. We then 
identified stearoyl-CoA desaturare-1 (SCD-1) as an important leptin regulated enzyme in 
the livers of aP2-nSREBP-lc mice and showed that leptin corrects hepatic steatosis by 
downregulating this enzyme. We also showed that leptin mediated SCD-1 
downregulation corrects hepatic steatosis by activating the AMPK pathway and hence 
increasing fatty acid oxidation in the livers of aP2-nSREBP-lc mice. However, 
correcting hepatic steatosis by downregulating SCD-1 was not enough to correct the 
diabetes of a6J/aZ/;aP2-nSREBP-lc mice (Chapter 4). In order to understand the 
molecular mechanisms by which leptin corrects insulin resistance, we then performed a 
subcutaneous leptin dose response study. We identified two suboptimal leptin doses, 
which improved insulin resistance without correcting hepatic steatosis. We then 
performed microarray studies to identify leptin-regulated genes important in insulin 
sensitivity (Chapter 5). Finally, in order to understand the efferent signals from the CNS 
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that mediate leptin's effects, w e studied leptin's effects in mice lacking all three 
P-adrenergic receptors (Chapter 6). Finally, the last part of this thesis is a discussion of 
all of our findings and future directions for this research (Chapter 7). 
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Chapter 2: Materials and Methods 
Materials and Methods from Chapter 3 
Mouse breeding and maintenance. aP2-nSREBP-lc mice were purchased from the 
Jackson Laboratory (Bar Harbor, Maine). aP2-nSREBP-lc males (C57BL/6J X SJL 
background) were crossed to C57BL/6J females. aP2-nSREBP-lc males and littermate 
controls generated from this cross were used in the following studies. All animals were 
housed on a 12 hour lightdark cycle at 23°C with free access to water and food. All 
procedures were in accordance with the guidelines of The Rockefeller University 
Laboratory Animal Research Center. 
Metabolic assays and procedures. Upon sacrificing the mice, plasma was obtained 
following centrifugation of blood collected on EDTA. We measured plasma leptin and 
insulin levels using mouse Elisa kits (R&D Systems Inc., Minneapolis, Minnesota and 
Alpco Diagnostics, Windham, New Hampshire, respectively). We determined plasma 
glucose, triglyceride and cholesterol levels using Glucose Trinder reagent, Infinity 
Triglycerides reagent and Infinity Cholesterol reagent, respectively (Sigma Chemical Co., 
St. Louis, Missouri). We measured liver triglycerides as previously described(Cohen et 
al. 2002). Histology was performed on livers fixed in 10% formalin and stained with 
hematoxylin and eosin. 
Intracerebiventricular (ICV) leptin treatment. Mice were studied between 14-18 weeks 
of age. Two weeks before leptin treatment, mice were individually caged. Baseline 
weight and food intake were measured every other day in the mid-light cycle. At the 
beginning of treatment, mice were divided into two weight-matched groups. One group 
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was treated with 12 ng/hr of recombinant mouse leptin (Amgen, Thousand Oaks. 
California) and the other was treated with PBS for 12 days. Mice were anesthetized 
using ketamine/xylazine, and a cannula connected to an Alzet miniosmotic pump (Alza 
Co., Palo Alto, California) was placed into their third ventricle as previously described 
(Halaas et al. 1997). During the treatment, food intake and body weight were recorded 
daily, and on day 12, mice were sacrificed during the mid-light cycle. 
Subcutaneous leptin treatment. aP2-nSREBP-lc mice were treated with 12ng/hr, 
25ng/hr, 50ng/hr, lOOng/hr, and 200ng/hr of recombinant mouse leptin or PBS for 12 
days using subcutaneously placed Alzet miniosmotic pumps, as previously described 
(Halaas et al. 1997). Food intake and weight were monitored as described above. 
Microarrays. RNA isolated from four individual liver samples was pooled, labeled and 
hybridized once to Affymetrix Murine MG-U74 Av2 chips according to Affymetrix 
protocols (Affymetrix Inc., Santa Clara, California). In specific cases, Affymetrix results 
were reconfirmed using real-time PCR Taqman assay. Initial analysis and comparisons 
were performed using a fold change cut-off of 1.5, change p-value<0.0025 and detection 
p-value of 0.05 in the experiment or baseline depending on the sign of the fold change. 
Cluster and correlation analysis. Cluster analysis was performed using standard 
hierarchical clustering with the average linkage method. The distance measure was (1-
p)/2, where p is the Pearson correlation function. 
Correlation analysis: For gene selection, a filter of 1.5 fold change and the standard 
Affymetrix values for change and detection p-values were used. A gene had to have a 
significant fold change in at least 5 samples to pass the filter. Correlation for genes in the 
intersecting set of pairs was calculated using an absolute log base 2 fold change cutoff 
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greater than 0.6, change p-value<0.0025 and detection p-value<0.04 (these p-values are 
the default ai and yi values for MAS 5.0 (Affymetrix Inc., Santa Clara, California). The 
criteria used are quite stringent for gene selection, and for most randomly matched pairs, 
a very small number of genes meet these criteria. This is critical because the distribution 
of random correlations is highly dependent on the number of points, with a small number 
of points having a much greater chance of being highly correlated than a large number of 
points. To minimize this problem, we changed the selection criteria for computing 
background statistics. This should not affect our results provided that the same statistic is 
used for all computations. We calculated the background correlation using the top 250 
genes ranked by absolute log fold change in the union set. Note that 250 is an arbitrary 
cutoff and we tested cases from 50-500 genes. However, we chose to report the 250 case 
since it was the most conservative one (i.e. highest p-value). We calculated the Pearson 
correlation coefficient: 
o = 
Y(.v,-.T](>,-r) 
# ^ 
a T v (»;->•)•' 
Where ^ is the mean of X and similarly for Y, and X and Y are the logs of the fold 
changes. To assess the significance of this correlation, we calculated the distribution of 
correlations for a large number of quasi-randomly paired samples. This model was 
"random" in the sense that 30 pairs of comparisons were paired arbitrarily (we did not 
mix samples from different tissue types) to create 95 fold-change files. We then 
exhaustively paired all 95 of these samples, ensuring that we were always looking at four 
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different samples at each time. This resulted in 3,692 sets for which we computed 
correlation coefficients. We looked at the distribution of the absolute value of the 
correlation coefficient. To calculate the p-value, we used the formula: p-value=[(N#> 
0.738)+1]/[(NTOtal)+1] where N# is the number of pairs with p>0.738 (4 in our case), 
and Ntotal is the total number of pairs. 
Statistical analysis. All data are expressed as means ± SE. An unpaired Student's t-test 
was used to determine significance. 
Materials and Methods from Chapter 4 
Mouse breeding and maintenance. Asebia (abJ/abJ) mice were purchased from the 
Jackson Laboratory. aZ//afr/;aP2-nSREBP-lc mice were generated by first crossing 
abJ/abJ (background information is available at 
http://www.informatics.jax.org/external/festing/mouse/docs/ABJ.shtml) to aP2-nSREBP-
lc mice to generate, a.zA+;aP2-nSREBP-lc males. These males were crossed with abJ/+ 
females to generate a^A^J;aP2-nSREBP-lc mice and littermate controls. Genotypes 
were determined by genomic PCR and Southern blotting. 
SCD enzymatic activity. Conversion of [l-14C]stearoyl-CoA to [l-14C]oleate was used to 
measure SCD enzyme activity from individual liver extracts as previously described 
(Cohen et al. 2002). 
Taqman. SCD-1 mRNA levels were quantitated using Taqman real-time PCR from 
individual livers with probes and primers designed for SCD-1. SCD-1 mRNA levels 
were measured in duplicate in aP2-nSREBP-lc mice, wild-type littermates and aP2-
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nSREBP-lc mice treated with ICV leptin, ICV PBS and several doses of peripheral 
leptin. A cyclophilin probe and primers were used in the same assay as the baseline. 
Fatty acid analysis. Total lipids were extracted from tissues according to the method of 
Bligh and Dyer as previously described (Bligh 1959). The fatty acids were quantitated by 
GLC as previously described (Miyazaki et al. 2001). Pentadecanoic acid (Sigma, St 
Louis, MO) was added as an internal standard for the quantitation of fatty acids. 
Extraction and measurement of ACC activity. Isolation of ACC was performed as 
previously described (Kudo et al. 1995). ACC activity in the 6% PEG 8000 fraction was 
determined using the [14C]bicarbonate fixation assay (Witters and Kemp 1992). 
Malonyl-CoA content determination. Malonyl-CoA levels in liver were measured using 
highly purified fatty acid synthetase as previously described (McGarry et al. 1978). 
Western blot analysis. 50 fxg of purified protein was loaded onto a 9% SDS-PAGE gel. 
The separated proteins were transferred to nitrocellulose membranes which were blotted 
using antibodies against phosphopeptides based on the amino acid sequence surrounding 
Thr 172 of the a subunit of human AMPK and Ser79 of rat ACC (Upstate, Waltham, 
MA). Protein levels of al and a2 AMPK, and ACC1, ACC2, and CPT1 were 
determined using specific antibodies (Alpha Diagnostic Int., San Antonio, TX). Anti-
AMPK al and a2 and anti-AMPK-pT 172 antibodies were obtained as described 
previously (Woods et al. 1996a; Sugden et al. 1999). The proteins were visualized using 
ECL as described by the manufacturer. 
Carnitine palmitoyltransferase I (CPT1) activity assay. CPT1 activity was measured in 
isolated mitochondria as previously described (Bremer 1981). Mitochondria were 
isolated essentially as described by Vance (Vance 1990). Briefly, mitochondrial protein 
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was added to assay medium containing 20 m M HEPES, pH 7.3, 75 m M K C L , 2 m M 
KCN, 1% fat free BSA, 70 uM palmitoyl-CoA and 0.25 mM L-[3H]-carnitine. Samples 
were incubated in 37°C for 3 minutes. The reaction was stopped by adding 0.5 ml 4 M 
ice-cold PCA. Mitochondria were centrifuged at 13,000 g for 10 minutes. The pellet was 
washed with 500 u.1 2 mM PCA and the centrifugation repeated. The resulting pellet was 
washed then resuspended in 800 \i\ ddH20 and extracted with 600 u.1 butanol. 300 u.1 of 
butanol phase was counted by liquid scintillation. 
Statistical analysis. All data are expressed as means ± SE. An unpaired Student's t-test 
was used to determine significance. 
Materials and Methods from Chapter 5 
Animal studies. Animals used in these studies were generated and studied the same way 
as previously described in Materials and Methods from Chapter 3. Metabolic parameters 
and assays as well as subcutaneous leptin treatment studies were performed as previously 
described in Materials and Methods from Chapter 3. 
Liver glycogen content. Liver glycogen was quantitated with the amyloglucosidase 
method as previously described (Keppler 1974; Soukas 2001). 
In vivo insulin stimulation and analysis of insulin signaling proteins. Male aP2-
nSREBP-lc mice were treated with either 50ng/hr of subcutaneous leptin or PBS for 12 
days. On day 12, mice were anesthesized with pentabarbitol after an overnight fast, and 
injected with 5 units of regular human insulin (Lilly Research Laboratories) into the 
inferior vena cava. Livers and muscles were excised after 5 minutes and freeze-clamped 
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in liquid nitrogen. Insulin signaling molecules were analyzed as previously described 
(Ueki et al. 2002). 
PI3K Assay and AKT kinase assay. Liver and muscle homogenates from the in vivo 
insulin stimulation were used to assay PDK and AKT kinase activities as previously 
described (Ueki et al. 2002). 
Fatty acyl CoA analysis. Tissue fatty acyl CoA concentrations were measured from 
tissues, which were freeze-clamped in liquid nitrogen as previously described (Yu et al. 
2002). 
Microarrays and Taqman gene expression. Microarray studies and real-time RT-PCR 
Taqman analysis were performed as previously described in Materials and Methods from 
Chapter 3. Sak, HNF6, G-6-Pase, FBPase and PEPCK mRNA levels were quantitated 
using Taqman real-time PCR from individual livers with probes and primers designed for 
sak, HNF-6, G-6-Pase, FBPase and PEPCK respectively. Cyclophilin primers and probe 
were used as an internal control. 
Cluster analysis. Before clustering, the genes were filtered to include those that had a 
fold change of 1.5 (up or down) and a change p-value of 0.001(as scored by the MAS 5.0 
software from Affymetrix). The genes were then clustered using an extension of the k-
means clustering algorithm (Hartigen 1975; Kohonen 1997). The basic procedure for k-
means clustering is to first specify the starting k cluster centers. Then the following two 
steps are repeated: (1) For each point in the data, find the cluster center it is closest to 
and assign it to that group, (2) for each group determined in step 1, find the mean of that 
group and set the new value of the cluster center to it. These steps were iterated until the 
amount by which the cluster center moved drops below 1 part in IO6 To prevent the 
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algorithm from getting trapped in a local minimum, we used a recursive technique (Duda 
1973) to begin clustering. In brief, we started by finding the mean of the entire dataset. 
We then iterated from 1 to k each time adding one more center to the problem. To go 
from any / - 1 toy means, the mean associated with the cluster with the largest variance 
was split into two closely separated points and then the standard &-means steps were 
performed. Finally, to further prevent the algorithm from being trapped, we ran the 
algorithm for 1,000 independent runs each seeded with a different random number so that 
the splitting procedure would be different for each run. To determine the best clustering 
trial for the final result, we computed the trace of the scattering matrices Tr (SbSw'), as 
previously described by Duda and Hart (Duda 1973) which measures the "average" 
separation between clusters divided by the "average" width of the clusters. We 
determined the optimal number of clusters by using a standard measure of cluster fit as a 
function of cluster number, the Davies-Bouldin index (Jain 1988). 
Statistical analysis. All data are expressed as means ± SE. An unpaired Student's t-test 
was used to determine significance. 
Materials and Methods from Chapter 6 
Animal studies, p -less mice and their littermate controls were generated as previously 
described (Bachman et al. 2002). 
Subcutaneous leptin treatment, p-less mice and their littermate controls were treated 
with subcutaneous recombinant mouse leptin or PBS for either 2 or 3 days or for 12 days 
using subcutaneously placed Alzet miniosmotic pumps as previously described (Halaas et 
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al. 1997). Food intake and weight were monitored as described in Materials and Methods 
from Chapter 3. 
Body composition analysis. Body composition was analyzed as previously described 
(Halaas et al. 1995). Carcasses were first weighed and then dried until the weight 
stabilized in a 90°C oven. The difference in weight was calculated as the total body 
water and then the carcass was homogenized and the total body fat was calculated by 
extracting it using a 3:1 mixture of chloroform:methanol using a soxhlet apparatus. The 
remaining weight was calculated as the total lean mass. 
Metabolic parameters. Metabolic parameters were measured as previously described in 
Material and Methods from Chapter 3. 
SCD mRNA and activity. SCD-1 mRNA and SCD activity were measured as previously 
described in Materials and Methods from Chapter 4. 
Gene expression analysis. Real-time Taqman multiplex RT-PCR analysis was used to 
measure the mRNA levels of HSL and UCP-1 from BAT mRNA using primers and probe 
specific for HSL and UCP-1 respectively. Primers and probe specific for 18S mRNA 
were used as an internal control. 
Statistical analysis. All data are expressed as means ± SE. An unpaired Student's t-test 
was used to determine significance. 
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Chapter 3: Site of leptin action in a rodent model of lipodystrophy 
Introduction 
Leptin is an adipocyte hormone that modulates energy balance, metabolism, the 
hypothalamic-pituitary axis and immune function (Zhang et al. 1994; Friedman 2000). 
Leptin also enhances insulin action, although the underlying mechanism has not been 
fully elucidated (Kamohara et al. 1997; Chinookoswong et al. 1999; Ogawa et al. 1999). 
Recently leptin was found to be highly effective for treating the diabetes, insulin 
resistance and hepatic steatosis associated with human lipodystrophy (Oral et al. 2002; 
Petersen et al. 2002). Leptin has similar effects in lipodystrophic rodents, most notably 
in aP2-nSREBP-lc transgenic mice. These animals express a truncated, constitutively 
active form of the SREBP-lc transcription factor under the control of the adipose-specific 
aP2 promoter and develop lipodystrophy with very low plasma leptin levels as well as 
hyperphagia, massive fat accumulation in peripheral tissues, hyperglycemia and 
hyperinsulinemia (Shimomura et al. 1998). In these mice, peripheral leptin 
administration corrects the metabolic abnormalities associated with lipodystrophy 
(Shimomura et al. 1999). In A-ZIP/F1 mice, a second form of rodent lipoatrophy, leptin 
also corrects insulin resistance and hepatic steatosis, albeit at higher doses(Moitra et al. 
1998; Ebihara et al. 2001). In these animals, fat transplants from wild-type, but not ob/ob 
mice, also ameliorate this condition confirming that leptin is necessary for the anti-
diabetic effects of fat transplants (Gavrilova et al. 2000; Colombo et al. 2002). Recently, 
leptin was shown to reverse the hyperglycemia and hyperinsulinemia associated with 
Irsl^IrsS7" lipoatrophic mice (Laustsen et al. 2002) 
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Leptin has been reported to act directly on a number of tissues including brain, 
skeletal muscle, heart and pancreatic p-cells (Kieffer et al. 1997; Cohen et al. 2001; 
Atkinson et al. 2002; Minokoshi et al. 2002). However, at present, neither the site nor the 
mechanism by which leptin corrects the abnormalities associated with lipodystrophy have 
been established. Here, we show that low dose intracerebroventricular (ICV) leptin 
corrected the metabolic abnormalities associated with lipodystrophy. ICV leptin 
treatment was able to correct both diabetes and hepatic steatosis associated with 
lipodystrophy as well as subcutaneous leptin treatment does. Moreover, comparison of 
hepatic gene expression following ICV and subcutaneous leptin treatment reveals that 
these gene expression profiles are highly correlated suggesting that leptin changes hepatic 
gene expression via the CNS. On the other hand, muscle gene expression following ICV 
and subcutaneous leptin treatment reveals that these gene expression profiles have a low 
correlation suggesting that leptin might have direct effects on muscle. In summary, our 
data suggests that leptin acts on the CNS in order to exert its metabolic effects in 
lipodystrophy. Furthermore, leptin regulates liver gene expression through its actions on 
the CNS. 
Results 
Central leptin administration in aP2-nSREBP-lc mice 
We administered recombinant murine leptin (12 ng/hr) or phosphate buffered 
saline (PBS) intracerebroventricularly to aP2-nSREBP-lc mice for 12 days (Halaas et al. 
1997) (Figure 3.1). In separate studies, lipodystrophic animals were treated with a higher 
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dose of subcutaneous leptin (200 ng/hr for 12 days) or PBS. This subcutaneous dose has 
previously been shown to fully correct the metabolic defects in lipodystrophic mice 
(Shimomura et al. 1999). ICV leptin (12ng/hr) did not change plasma leptin levels in 
lipodystrophic mice (Figure 3.1a). In animals treated with ICV leptin, food intake was 
reduced by 26.2% (Figure 3.1b) and body weight was reduced by 17.3% (Figure 3.1c) 
relative to PBS treated controls. This dose of ICV leptin treatment markedly improved 
insulin sensitivity, as both plasma glucose and insulin levels were significantly lowered 
(Figure 3.1d and e). Finally, ICV leptin treatment decreased liver triglyceride levels 
seven-fold (Figure 3.2a) and reduced liver mass by 67.5% relative to PBS treated controls 
(Figure 3.2b). Histological analysis confirmed that ICV treatment corrected the fatty 
liver of aP2-nSREBP-lc mice (Figure 3.2c). As an additional control, we treated a 
separate group of aP2-nSREBP-lc mice with 12 ng/hr of peripheral leptin, the same dose 
used in the ICV treatment. This dose had no effect on any of the parameters shown in 
Figures 3.1 and 3.2 (data not shown). In all cases, ICV leptin was as or more potent than 
a much higher dose of peripheral leptin in correcting the metabolic abnormalities 
associated with lipodystrophy. These data suggest that leptin's effects on insulin action, 
diabetes, and hepatic steatosis in lipodystrophy can be mediated exclusively via the CNS. 
Comparison of gene expression in icv and subcutaneous leptin treated aP2-
nSREBP-lc livers 
We next compared liver gene expression profiles in aP2-nSREBP-lc and wild 
type mice with and without peripheral or central leptin treatment. mRNAs for several 
enzymes involved in fatty acid synthesis, glycolysis and gluconeogenesis have been 
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Figure 3.1 Effects of central and peripheral leptin in rodent lipodystrophy. 
Several metabolic parameters in aP2-nSREBP-lc transgenic mice treated with 
icv PBS, icv leptin (12 ng/h), and subcutaneous leptin (200ng/h) are shown. 
(a, d, and e) Plasma levels of leptin, glucose, and insulin respectively. 
(b) Average daily food intake for the 12-day treatment, (c) Percentage change 
in body weight. One hundred percent change indicates the weight of the mice 
on the day of pump insertion. Error bars indicate the SE for four mice per group 
for each treatment. *P < 0.05, icv leptin vs. icv PBS. 
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Figure 3.2 Correction of fatty liver with central leptin treatment. 
(a) Liver triglyceride content, (b) Liver mass in grams. Error bars indicate 
the SE for four mice per group for each treatment. *P  0.05, icv leptin
vs. icv PBS. (c and d) Representative liver sections from mice treated with 
icv PBS and icv leptin. Original magnification, X200 ; scale bars: 100 um. 
found to be differentially expressed in livers of aP2-nSREBP-lc mice and normalized by 
peripheral leptin treatment (Shimomura et al. 2000). We examined the expression 
profiles of a group of genes known to regulate lipid and glucose metabolism following 
either central or peripheral leptin administration (Table 3.1). For each of these genes, an 
equivalent or greater response was evident after ICV leptin treatment. For example, 
malic enzyme and fatty acid synthase, enzymes involved in fatty acid synthesis, were 
upregulated 3.0 and 3.7-fold respectively in aP2-nSREBP-lc relative to wild type liver. 
These two genes were downregulated 7.0 and 4.3-fold respectively after ICV leptin 
administration versus 2.6 and 2-fold respectively after peripheral leptin treatment 
(relative to PBS treated transgenic livers). In aP2-nSREBP-lc livers, pyruvate kinase, a 
glycolytic enzyme, and glucose-6-phosphatase, a gluconeogenic enzyme, were 
upregulated 3.0 and 3.3-fold respectively relative to wild type livers. ICV leptin 
treatment downregulated these genes 7.0 and 4.3-fold respectively, and peripheral leptin 
administration downregulated them 2.5 and 1.5-fold respectively (relative to PBS treated 
transgenic livers). Expression level of these genes was normalized to wild type levels 
following ICV leptin treatment. Several other genes were similarly regulated by both 
central and peripheral leptin, with most genes more strongly regulated by ICV than by 
peripheral leptin (see Supplementary Tables 1 and 2 online; 
http://www.jci.0rg/cgi/content/ft1ll/l 13/3/414/DC1). Furthermore, many of the genes that 
were altered between lipodystrophic and wild type livers were also differentially 
expressed in livers of ob/ob mice compared to wild type mice, indicating that the 
alterations in liver gene expression in aP2-nSREBP-lc mice resemble those of congenital 
leptin deficiency (Cohen et al. 2002). 
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Accession number 
J02652 
D63764 
X13135 
U00445 
AW122523 
U10374 
X85983 
X58426 
U95945 
X74938 
AB033887 
Name 
Malic enzyme 
Pyruvate kinase 
Fatty acid synthase 
Clucose-6-phosphatase 
L-chain fattyacyl elongase 
PPARy 
Carnitine aceyltransferase 
Hepatic lipase 
HNF6 
HNF3Y 
Fatty acyl-CoA ligase 
Function 
Lipid metabolism 
Glucose metabolism 
Lipid metabolism 
Glucose metabolism 
Lipid metabolism 
Transcription factor 
Lipid metabolism 
Lipid metabolism 
Transcription factor 
Transcription factor 
Lipid metabolism 
Fold change 
icv leptin 
-6.96 
-6.96 
-4.29 
-4.29 
-6.96 
-6.96 
-2.14 
2.14 
3.03 
1.74 
2.30 
Subcutaneous 1 
-2.64 
-2.46 
-2.00 
-1.52 
-3.25 
-1.52 
-1.62 
1.62 
2.83 
2.14 
1.87 
The line space seperates the genes downregulated by leptin treatment (above the I line space) from the genes 
upregulated by leptin treatment (below the line space) 
Table 3.1 Hepatic gene expression comparison between icv leptin and subcutaneous leptin treatment. 
Comparison of gene expression regulated by icv leptin versus subcutaneous leptin in livers of aP2-nSREBP-lc 
transgenic mice. 
Computational analysis of hepatic and muscle transcription profiles 
In order to extend the analysis of gene expression beyond the comparison of a few 
key genes, we used standard hierarchical clustering to assess the similarity of central 
versus peripheral leptin treatment (Figure 3.3a). In the resulting dendrogram, the 
transcriptional profiles in liver after subcutaneous and ICV leptin treatments clustered 
together, indicating that the gene expression pattern of ICV leptin treatment was more 
similar to the 200 ng/hr dose of peripheral leptin treatment than to any others tested. 
In order to provide more robust quantitative information on how significant the 
similarities were, we developed a novel approach to determine the significance of the 
similarity (correlation) between the transcriptional profiles in liver following ICV and 
subcutaneous leptin administration. We compared the global gene expression profiles of 
ICV and subcutaneous leptin treatment using two methods: 1) correlation analysis 
between genes that are similarly regulated in both experiments, in what is referred to as 
the intersection set, and 2) correlation analysis among genes that are regulated in either or 
both experiments, in what is referred to as the union set. For both methods, we first 
calculated the ratio of gene expression between ICV leptin versus ICV PBS treatment and 
then subcutaneous leptin versus subcutaneous PBS treatment. It was necessary to 
establish the ratio of gene expression in the ICV leptin and subcutaneous leptin treated 
samples relative to their own controls because the insertion of ICV and subcutaneous 
pumps each have distinct background effects. In the first method, the standard "detection 
p-values" and "change p-values" from the Affymetrix software were used to identify 
leptin-regulated genes with an absolute fold change cutoff of 1.5 relative to controls. 
58 
aP2nSREBP1c male liver (12ng/hr peripheral leptin) 
aP2nSREBP1c male liver (25ng/hr peripheral leptin) 
oP2nSREBP1c mate Ivw (200ngrt» pei^ h«rt leptti) 
aPfciSREBPIc mate h w (12r«/hr cwiH toptti) 
aP2nSREBP1c male liver (100ng/hr peripheral leptin) 
aP2nSREBP1c male liver (50ng/hr peripheral leptin) 
wildtype female hypolhalamus (leplm) 
wildtype female hypethalamus (leptin withdrawal Day/) 
wildtype hypothalamus (tasted) 
wildtype female hypethalamus 
wildtype female hypothalamus (leplm wilhdrawal Day2) 
wildtype female hypothalamus (leplm withdrawal Dayl) 
wildtype female hypothalamus (leplm withdrawal Day3) 
aP2nSREBP1c female muscle (peripheral PF) 
aP2nSREBP1c female muscle (200ng/hr peripheral leptin) 
aP2nSREBP1c female muscle (penpehral PBS) 
aP2nSREBP1c female muscle (no treatment) 
wildtype male liver (no treatmenl) 
ob/ob female liver (no treatment) 
aP2nSREBP1c male liver (no treatment) 
aP2nSREBP1c male liver (central PBS) 
aP2nSREBP1c male liver (peripheral PBS) 
aP2nSREBP1cfemale liver (peripheral PF) 
aP2nSREBP1 c female liver (peripheral PBS) 
aP2nSREBP1c female liver (no treatmenl) 
aP2nSREBP1c female liver (200ng/hr peripheral leplm) 
wildtype female liver (no treatment) 
0 1 
_ l _ 
02 
l 
Distance 
03 04 
? 
^ 
? 
10-"' 
- 1st quadrant 
-
0 
0 o 
o ° o 
" ° ° 
3rd quadrant 
! I 
2nd quadrant 
0 -' 
o o . - p =0 . 9 
Jtf&tJt* °slope=0.6 
o 
o 
4th quadrant 
l i 
10 1 10 
ICV Leptin vs ICV PBS 
Distribution of Correlations 
co 
CD 
Cl 
102 -
101 -
1 
-io1 -
10"3 -
1st quadrant 
o oJHm 
° <° 
o 
3rd quadrant 
o 
o ^ 
< 
2nd quadrant 
o 
tf>°<,J / * ° ° P =074 
iflb^oo slope-0 5 
•R o w 
'o " 
o 
I 
4th quadrant 
I l 
10~z 10"1 1 10' 
ICV Leptin vs. ICV PBS 
10-' 
ICV vs Subcutaneous 
Leptin Treatment 
t l T T f M f h T T T h f H ^ >y 
0 2 0 4 0 6 
Correlation 
Figure 3.3 Computational analyses of the hepatic transcription profile after icv and subcutaneous leptin 
treatment. Cluster analysis, correlation analysis,and the distribution of correlations of liver gene expression 
from mice treated with icv leptin versus icv PBS and subcutaneous leptin versus subcutaneous PBS are shown. 
(a) Standard hierarchical clustering of 30 microarray experiments, including icv leptin and subcutaneous 
leptin treatments, show that the transcription profiles of icv and subcutaneous leptin are more similar to 
each other than to any other sample, (b) A pairwise comparison of icv and subcutaneous leptin gene 
expression is shown for genes regulated by both treatments (the intersection set). In the first quadrant, 
gene expression is increased in subcutaneous treatment and decreased in icv treatment; in the second 
quadrant, gene expression is increased in both treatments; in the third quadrant, gene expression is 
decreased in both treatments; and in the fourth quadrant, gene expression is decreased in subcutaneous 
treatment and increased in icv treatment. In almost all cases, gene expression is similarly regulated by 
both treatments, r denotes the correlation value, (c) The logarithm of fold changes of subcutaneous leptin 
versus PBS and icv leptin versus PBS for genes regulated by either treatment (the union set) is shown. 
(d) The distribution of correlations of 3,962 pairwise comparisons from our database is shown. The arrow 
shows the correlation of the icv leptin versus PBS treatment and thesubcutaneous leptin versus PBS 
treatment. This shows that gene expression after icv and subcutaneous leptin is more highly correlated than 
for the other comparisons (P < 0.002). 
From this, w e compiled two distinct lists of leptin-regulated genes: one from the ICV 
leptin treatment and another from the subcutaneous leptin treatment (each relative to its 
own control; see Supplementary Tables 3, 4, 5 and 6 online; 
http://www.jci.Org/cgi/content/ftill/113/3/414/DCl). Expression of 185 genes changed 
following both leptin administration protocols (i.e. ICV and subcutaneous). A linear 
regression of the logarithms of the fold changes in the intersection set showed a slope of 
0.6 for peripheral leptin versus ICV leptin and a correlation coefficient of 0.897 (Figure 
3.3b). The slope of 0.6 indicated that, in general, ICV leptin treatment had a greater 
effect than subcutaneous leptin administration. Even though 0.897 is an intrinsically high 
correlation coefficient, we further evaluated the significance of this correlation by 
analyzing the patterns of all genes that changed in abundance after either treatment 
modality. In order to establish the statistical significance of this correlation, we 
calculated a background correlation from 30 microarray experiments previously 
performed in our laboratory (see Supplementary Table 7 online; 
http://www.jci.Org/cgi/content/full/113/3/414/DCl) and matched them into a total of 
3692 pairs. Initially, we looked for genes that were similarly regulated in both samples in 
the pairwise comparison (i.e. the intersection set) but found that only ~ 10% of the 3692 
pairs had a number of genes comparable to the 185 identified in ICV versus subcutaneous 
leptin treatment. Because there were an insufficient number of genes in the intersection 
set for most of the 3692 pairs, we modified the analysis by computing the correlation of 
genes in the union set for the lists of regulated genes. There were 379 genes in the union 
set of ICV leptin versus PBS and subcutaneous leptin versus PBS treatment. In this 
analysis, the correlation of ICV versus subcutaneous leptin treatment was 0.738 (Figure 
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3.3c), with a calculated p-value of approximately 0.0014. This correlation was among 
the highest correlations observed among the 3692 pairs of samples that were studied, 
indicating that the transcriptional response to ICV and subcutaneous leptin is highly 
similar (Figure 3.3d). A list of the RNA sources from the top 25 pairwise comparisons 
can be found in Supplementary Table 8 online at 
http://www.jci.Org/cgi/content/full/113/3/414/DCl. The comparisons producing 
equivalent correlations to that of ICV versus subcutaneous leptin were invariably 
between very similar samples, such as between a wild type liver and liver from a leptin 
treated aP2-nSREBP-lc mouse. Leptin is known to normalize the liver phenotype of 
these animals (see above) (Shimomura et al. 1999). Another strong similarity was 
between ob/ob liver and PBS treated aP2-nSREBP-lc liver. The livers from these 
animals are both steatotic and this comparison is essentially between two leptin deficient 
livers (see above). Other pairwise analysis with high correlations included comparisons 
between untreated or PBS treated tissue or treatment with subtherapeutic doses of leptin 
(i.e.; low doses that have no biologic effect). 
Transcription profiles in skeletal muscle. 
As muscle is the primary site of insulin stimulated glucose disposal, we also 
analyzed gene expression profiles in skeletal muscle of aP2-nSREBP-lc transgenic mice 
following ICV and subcutaneous leptin administration. In contrast to the effects of leptin 
on gene expression in liver, gene expression in skeletal muscle was largely unchanged by 
central and peripheral leptin. The genes that were leptin regulated included major urinary 
protein group 1, acetyl CoA dehydrogenase, dienoyl-CoA isomerase ECHlp and fatty 
61 
acid binding protein 3. Consistent with other findings, the correlation between central 
and peripheral leptin was relatively low (Figure 3.4), suggesting that leptin might directly 
influence gene expression in muscle but not in liver (Minokoshi et al. 2002). 
Discussion 
Leptin has potent antidiabetic and antisteatotic effects in human and rodent 
lipodystrophy (Shimomura et al. 1999; Oral et al. 2002). Our findings strongly suggest 
that leptin's metabolic effects and its actions on liver gene expression in lipodystrophy 
are indirect via the CNS. This conclusion is consistent with data from ICV treatment of 
leptin deficient ob/ob and wild type mice (Halaas et al. 1995). Furthermore, mice with a 
neuron-specific knockout of the leptin receptor are obese and develop hepatic steatosis, 
while mice with a liver-specific knockout do not (Cohen et al. 2001). This conclusion is 
also consistent with previous studies showing that the CNS plays an important role in 
regulating glucose homeostasis (Miles et al. 1991). Several recent reports suggest that 
leptin can exert direct effects on peripheral tissues. Leptin increases fatty acid oxidation 
in skeletal muscle by activating AMP-activated protein kinase (AMPK), which in turn 
phosphorylates and inactivates ACC (Minokoshi et al. 2002). Leptin has also been 
suggested to activate fatty acid oxidation in heart independent of AMPK activation 
(Atkinson et al. 2002). In liver, leptin is suggested to increase fatty acid oxidation by a 
mechanism dependent on PPARa (Lee et al. 2002). While our results do not exclude the 
possibility that direct actions of leptin on peripheral tissues such as muscle may 
contribute to its effects in lipodystrophy, these actions are not required for the metabolic 
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Figure 3.4 Computational analyses of the muscle transcription 
profile after icv and subcutaneous leptin treatment. A pairwise 
comparison of icv and subcutaneous leptin gene expression is shown 
for genes regulated by either treatment (the union set), r denotes 
the correlation value. 
improvement observed following leptin treatment. This is because the abnormalities in 
aP2-nSREBP-lc mice were corrected by central leptin administration at doses that had no 
effect on plasma leptin levels. 
Finally, we utilized a novel approach that quantifies the extent of similarity 
between two pairs of samples and computes the significance of the correlation to 
compare the effects of central and peripheral leptin. This analysis revealed a nearly 
identical set of effects of ICV and subcutaneous leptin on liver gene expression. This 
type of analysis is potentially relevant in other settings, including clinical pathology and 
could be used to determine the significance of the similarity of two tumor samples. 
However, the analyses of microarray data do suggest that peripheral leptin has distinct 
effects on gene expression in skeletal muscle compared to central leptin. While the data 
from the CNS leptin infusions suggest that these effects are not essential for leptin's 
actions, the physiological relevance of these direct effects can be further investigated 
using mice with a muscle specific knockout of the leptin receptor (Bruning et al. 1998; 
Cohen et al. 2001). These results showed that for the vast majority of leptin regulated 
genes ICV leptin is even more potent than a much higher dose of peripheral leptin. This 
includes the RNAs for several SREBP-lc regulated genes, which are generally repressed 
by leptin. However, in this case, we did not observe a change in the RNA levels of 
SREBP-lc itself. It is possible however that SREBP-lc is regulated at the post-
transcriptional level and that, as previously shown in adipose tissue, leptin influences the 
amount of SREBP cleavage in liver (Soukas et al. 2000). 
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Chapter 4: Role of Leptin regulated genes in Hepatic Steatosis and Diabetes: 
SCD-1 and Hepatic Steatosis in Lipodystrophy 
Introduction 
Recently, SCD-1 was shown to be an important mediator of leptin's weight 
reducing and antisteatotic effects (Cohen et al. 2002). SCD is a rate-limiting enzyme in 
the triglyceride biosynthesis pathway and it converts saturated fatty acids into 
monounsaturated fatty acids by introducing a double bond between carbons 9 and 10 
(Ntambi and Miyazaki 2003). SCD converts its preferred substrates palmitoyl-CoA and 
stearoyl-CoA into palmitoleoyl-CoA and stearoyl-CoA (Ntambi 1999). There are several 
SCD isoforms, SCD-1 is mainly expressed in adipose tissue and liver, SCD-2 is mainly 
expressed in brain, SCD-3 is abundant in Harderian gland and SCD-4 was recently 
cloned in heart (Miyazaki et al. 2003). There is only one SCD isoform in humans, which 
is highly homologous to mouse SCD-1 isoform (Cohen et al. 2003). 
Recently, a number of studies in leptin-deficient ob/ob mice and in SCD-1 
knockout mice showed the importance of this enzyme in lipid metabolism. SCD-1 
knockout mice were shown to have reduced adiposity and these mice are resistant to diet-
induced obesity on high fat diet. There is an increase in energy expenditure and oxygen 
consumption in these mice. Moreover, these animals have reduced plasma leptin and 
insulin levels and were suggested to have increased insulin sensitivity (Ntambi et al. 
2002; Rahman et al. 2003). In the livers of leptin-deficient ob/ob mice, both SCD-1 
mRNA levels and activity were increased and leptin treatment reduced it back to wild-
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type levels or lower. When asebia mice (abJ/abJ), which have a deletion in the SCD-1 
gene, were crossed to ob/ob mice, there was a significant reduction in their obesity and a 
significant increase in their energy expenditure. Hepatic steatosis associated with leptin-
deficiency in ob/ob mice was also significantly improved (Cohen et al. 2002). The 
mechanism by which SCD deficiency causes its metabolic effects and its role in insulin 
sensitivity still remains unknown. 
In these studies, we studied the role of SCD-1 in leptin-mediated correction of 
hepatic steatosis and insulin resistance in lipodystrophy. First, we studied SCD-1 mRNA 
expression and activity in the livers of aP2-nSREBP-lc mice and showed that both 
mRNA expression and SCD enzymatic activity were significantly increased in the livers 
of aP2-nSREBP-lc mice compared to wild type mice. We then showed that ICV leptin 
treatment was able to repress SCD-1 mRNA levels and activity in the livers of 
lipodystrophic animals. The contribution of SCD-1 to the diabetic and steatotic 
phenotype of lipodystrophic mice was then assessed in crosses to SCD-1 deficient 
(asebia) mice. These studies showed that leptin acts via the CNS to reduce SCD-1 
mRNA levels and activity in liver, thereby improving hepatic steatosis. 
Results 
Role of SCD-1 in lipodystrophic fatty liver 
The microarray studies of hepatic gene expression in aP2-nSREBP-lc mice, wild 
type mice, ICV leptin treated aP2-nSREBP-lc mice and subcutaneous leptin treated aP2-
nSREBP-lc mice showed that the levels of hepatic SCD-1 mRNA were elevated in 
lipodystrophic livers and reduced by both central and peripheral leptin treatments. Real-
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time RT-PCR (Taqman) analysis showed that m R N A level for SCD-1 was elevated 2.3 
fold in the liver of aP2-nSREBP-lc mice relative to wild type mice and its enzymatic 
activity was increased 3.8-folds. ICV leptin administration reduced SCD-1 mRNA levels 
5.2-fold versus a 3.2-fold decrease for peripheral leptin treatment (Figure 4.1a). SCD 
enzyme activity was reduced 87.4% with ICV leptin infusion and 68.2% with 
subcutaneous leptin administration relative to PBS treated controls (Figure 4.1b). Both 
SCD-1 mRNA levels and SCD enzymatic activity were corrected to wild type levels 
following either treatment. 
To determine the extent to which high levels of SCD contribute to the fatty liver 
and insulin resistance of aP2-nSREBP-lc mice, we generated aP2-nSREBP-lc transgenic 
mice lacking SCD-1. The resulting abJ/abJ;aP2-nSREBP-\c mice remained 
lipodystrophic, possessing virtually no white adipose tissue. However, in ab /ab ;aP2-
nSREBP-lc mice, the gross liver appearance was markedly improved (Figure 4.2a). 
Histological sections of the livers showed a marked reduction in the number of lipid 
droplets (Figure 4.2b) and liver triglyceride levels were significantly reduced (Figure 
4.2c). Furthermore, in aP2-nSREBPlc mice, the hepatic levels of 16:1 and 18:1 
monounsaturated fats were increased compared to livers of wild-type mice. SCD-1 
deficiency in a6J/tfZ/;aP2-nSREBP-lc mice, decreased the relative levels of 
monounsaturated fats to wild type levels (Figure 4.2d). 
Mechanism for SCD-1 deficiency's metabolic effects 
Leptin was shown to increase fatty acid oxidation in muscle by phosphorylating 
and activating AMPK pathway, which in turn activates fatty acid oxidation through ACC 
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Figure 4.2 Correction of fatty liver in abJ/abJ;aP2-nSREBP-lc transgenic mice, (a) Cross 
liver appearance in abJ/abJ;aP2-nSREBP-lc transgenic mice, aP2-nSREBP-lc transgenic 
mice, and W T mice, (b) Representative liver sections from aP2-nSREBP-lc and abJ/abrl;aP2-
nSREBP-lc mice. Original magnification, X200; scale bars: 100 um. (c) Liver triglyceride 
levels, (d) Fatty acid content in liver. Error bars indicate the SE; n = 7 for the 
aP2-nSREBP-lc group, n = 6 for the abJ/abJ;aP2-nSREBP-lc group, and n = 3 for the 
abVatr1 group. *P < 0.05, abJ/abrJ;aP2-nSREBP-lc vs. aP2-nSREBP-lc mice; fP < 0.05, 
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inactivation and malonyl CoA downregulation (Minokoshi et al. 2002). To determine if 
SCD-1 deficiency improves hepatic steatosis in lipodystrophy through downregulating 
the AMPK pathway, we studied this pathway's components in the livers of aP2-nSREBP-
lc mice, abJ/abJ;aP2-nSKEBP-\c mice and wild-type mice. There was no difference in 
AMPK phosphorylation between wild type and aP2-nSREBP-lc mice however, AMPK 
phosphorylation was increased in a&J/afr/;aP2-nSREBP-lc mice relative to aP2-nSREBP-
lc mice suggesting that AMPK activity will also be increased in acAa6J;aP2-nSR£BP-lc 
mice relative to aP2-nSREBP-lc mice (Figure 4.3a). AMPK specifically phosphorylates 
Ser79 on ACC. There was no difference in ACC Ser79 phosphorylation in aP2-nSREBP-
lc mice relative to wild type mice. However, consistent with increased AMPK 
phosphorylation, there was an increase in ACC Ser79 phosphorylation in abJ/abJ;aP2-
nSREBP-lc mice relative to aP2-nSREBP-lc mice. Furthermore, ACC1 and ACC2 
protein levels were higher in aP2-nSREBP-lc transgenic mice compared to wild-type 
mice (Figure 4.3b). ACC protein levels were decreased in abJ/abJ;aP2-r\SP£BP-lc mice 
relative to aP2-nSREBP-lc mice. Consistent with the decreased protein levels and 
increased phosphorylation, ACC activity was also significantly decreased in abJ/abJ;aP2-
nSREBP-lc mice (Figure 4.3b). Decreased ACC activity also led to a significant 
decrease in malonyl CoA levels in aZ>-//afr/;aP2-nSREBP-lc mice which were 
significantly elevated in aP2-nSREBP-lc mice compared to wild type levels (Figures 
4.3c). A decrease in malonyl CoA levels would be expected to result in increased 
mitochondrial CPT-1 activity. When we measured CPT-1 activity, there was a 
significant increase in CPT-1 activity in abJ/abJ;aP2-nSREBP-\c mice compared to aP2-
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nSREBP-lc mice (Figure 4.3d). Increased CPT-1 activity would then increase 
mitochondrial fatty acid import and fatty acid oxidation in abJ/abJ;aP2-nSREBP-\c mice. 
Role of SCD-1 deficiency in glucose metabolism 
Despite improved hepatic steatosis, abJ/abJ;aP2-nSREBP-lc animals were 
hyperglycemic with glucose levels as high or higher than those of standard aP2-nSREBP-
lc transgenic mice (Figure 4.4a). abJ/abJ;aP2-nSREBP-lc mice had lower levels of 
insulin than aP2-nSREBP-lc transgenic mice (Figure 4.4b), which coupled with the 
higher glucose levels, suggested that there was (3-cell failure. It has been previously 
suggested that accumulation of saturated fatty acids in a cell can lead to apoptosis 
(Listenberger et al. 2003). These data might suggest that lipid content and SCD-1 
activity might also influence |3-cell function or viability. Plasma triglycerides, cholesterol 
and free fatty acids (FFA) were unchanged in afr//a6'/;aP2-nSREBP-lc mice versus aP2-
nSREBP-lc controls (data not shown). 
Real-time PCR (Taqman) analysis of hepatic gene expression showed that gene 
expression of three key enzymes in the gluconeogenesis pathway were upregulated in 
abJ/abJ;aP2-nSREBP-lc mice compared to aP2-nSREBP-lc mice. PEPCK gene 
expression was upregulated 1.3 folds (Figure 4.5a), G-6-Pase expression was increased 
1.7 folds (Figure 4.5b) and F,16BPase expression was 1.2 folds higher (Figure 4.5c) in 
a6J/a&J;aP2-nSREBP-lc mice relative to aP2-nSREBP-lc mice. Furthermore, gene 
expression of peroxisome proliferator-activated coactivator-1 (PGC-1) which is 
suggested to activate gluconeogenesis and fatty acid oxidation was also increased 
significantly in the livers of abJ/abJ;aP2-nSREBP-\c mice (Barthel and Schmoll 2003). 
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Figure 4.5 Gene expression analysis in the livers of aP2-nSREBP-lc mice and abVab^aPZ-nSREBP-lc mice. 
a. Taqman real-time PCR using primers and probes specific for PEPCK. b. Taqman real-time PCR using primers 
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PGC-1 m R N A levels were 1.6 folds higher in abJ/abJ ;aP2-nSREBP-I c mice relative to 
aP2-nSREBP-lc mice (Figure 4.5d). Expression of Foxol was also increased 1.3 folds in 
afr//a6'/;aP2-nSREBP-lc mice (Figure 4.5e). 
Discussion 
Recent data suggested that leptin reduces adiposity and liver triglyceride content, 
in part by reducing SCD-1 mRNA and enzymatic activity (Cohen et al. 2002; Ntambi et 
al. 2002). Our data is consistent with the possibility that leptin's effects to correct hepatic 
steatosis in lipodystrophy are also mediated, at least in part, by inhibiting SCD-1. Thus 
SCD-1 deficiency markedly improves hepatic steatosis in lipodystrophic animals. In 
aP2-nSREBP-lc transgenic mice, both SCD-1 mRNA levels and enzymatic activity were 
increased relative to wild type controls. ICV leptin treatment significantly reduced SCD-
1 mRNA levels and enzymatic activity. This suggests that efferent signals from the CNS 
are capable of repressing this enzyme. It was previously shown that saturated fatty acyl 
CoAs can inhibit ACC, an effect which would decrease cellular malonyl CoA levels 
(Volpe and Vagelos 1976; Lunzer et al. 1977). A decrease in malonyl CoA would be 
expected to de-repress the activity of carnitine palmitoyltransferase 1 (CPT-1), the rate-
limiting enzyme for the mitochondrial import and oxidation of fatty acids (McGarry et al. 
1977). The data reported here further suggest that repression of SCD-1 is associated with 
increased AMPK phosphorylation, which in turn would increase its activity. In muscle, 
leptin was shown to phosphorylate and hence increase AMPK activity, which in turn 
regulates leptin's fatty acid oxidation effects in this tissue (Minokoshi et al. 2002). Our 
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data further showed that increased A M P K activity was also associated with increased 
Ser79 phosphorylation and hence with reduced levels of ACC enzymatic activity. 
Decreased ACC activity then resulted in decreased malonyl CoA levels and increased 
mitochondrial CPT-1 activity. An increase in CPT-1 activity is expected to increase fatty 
acid import and (3-oxidation in mitochondria In the livers of SCD-1 knockout mice and 
abJ/abJ;ob/ob mice, SCD-1 deficiency is suggested to act through a similar mechanism of 
AMPK activation resulting in increased mitochondrial oxidation of palmitoyl-CoA 
(Dobrzyn et al. 2004). Other mechanisms might also contribute to the anti-steatotic 
effects of a deficiency of this enzyme. 
While the CNS pathways and efferent signals responsible for SCD-1 repression 
by leptin are unknown, some of leptin's effects might be mediated by repression of 
neuropeptide Y (NPY). Leptin is known to repress NPY gene expression in 
hypothalamus and NPY infusions induce liver ACC activity as well as other lipogenic 
genes (Zarjevski et al. 1993). SCD-1 gene expression was recently shown to be reduced 
in MCH'/';ob/ob mice suggesting that leptin's effects on SCD-1 expression may also be 
mediated by regulation of melanin-concentrating hormone (MCH) in the lateral 
hypothalamus (Segal-Lieberman et al. 2003). Recently ICV MTII injections were shown 
to decrease SCD-1 expression suggesting that leptin represses SCD-1 through 
melanocortin receptors (Lin et al. 2003). 
Previous data suggested that SCD-1 knockout mice have increased insulin 
sensitivity compared to wild type mice (Ntambi et al. 2002). Furthermore, SCD-1 
knockout mice had increased insulin signaling in muscle. In the muscle of SCD-1 
knockout mice, glucose uptake, as well as glycogen content, were increased. There was 
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also decreased P T P 1 B activity in the muscles of SCD-1 knockout mice (Rahman et al. 
2003). While SCD-1 deficiency reduced hepatic steatosis in lipodystrophic aP2-
nSREBP-lc mice, these animals remained severely diabetic. This suggests that leptin's 
anti-diabetic effects are not simply a result of its ability to reduce triglyceride levels in 
peripheral tissues. It is still possible however that other lipid moieties that modulate 
insulin sensitivity remain unchanged in the absence of SCD-1 (Shulman 2000). It is also 
possible that the decreased plasma levels indicate improved insulin sensitivity rather than 
(3-cell failure. The residual diabetes of a^AcV/;aP2-nSREBP-lc mice is consistent with 
the finding that pair-feeding aP2-nSREBP-lc transgenic mice significantly reduces liver 
triglycerides to near normal levels, while the mice remain diabetic (Shimomura et al. 
1999). Similarly ob/ob mice lacking PPARy in liver have a significant reduction in liver 
triglyceride levels while remaining hyperglycemic and insulin resistant (Matsusue et al. 
2003). Thus, reducing the liver triglyceride content of lipodystrophic mice is by itself 
insufficient to correct their diabetes. 
Our data suggests that SCD-1 deficiency in liver activated fatty acid oxidation in 
this tissue. It is suggested that fatty acid oxidation increases plasma free fatty acids, 
which in turn activate gluconeogenic enzymes thus increasing hepatic glucose output. 
Furthermore, fatty acid oxidation is suggested to provide precursors for gluconeogenesis, 
which in turn also increase hepatic glucose output (Elks 1990; Lam et al. 2003). Plasma 
insulin levels were lower in atV//acV/;aP2-nSREBP-lc mice compared to aP2-nSREBP-lc 
mice and it is known that insulin inhibits gluconeogenesis by suppressing gluconeogenic 
gene expression (Barthel and Schmoll 2003). Gene expression of key gluconeogenic 
enzymes were upregulated in livers of a&Az./y/;aP2-nSREBP-lc mice compared to aP2-
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nSREBP-lc mice. PEPCK, G-6-Pase and Fl,6BPase gene expression were all 
moderately upregulated in acV//atV/;aP2-nSREBP-lc mice compared to aP2-nSREBP-lc 
mice which already had higher expression levels of these enzymes compared to wild type 
mice (data not shown) (Shimomura et al. 2000). The further upregulation of 
gluconeogenic enzymes might be through PGC-1 upregulation. PGC-1 a is known to 
activate gluconeogenesis through HNF4a and fatty acid oxidation via PPARa (Koo et al. 
2004). PGC-1 expression was significantly increased in the livers of abJ, abJ \aP2-
nSREBP-lc mice. Forkhead transcription factor Foxol, which is also implicated in the 
activation of gluconeogenic enzymes through PGC-1 (Puigserver et al. 2003) was also 
modestly increased in the livers of afr/Afr/;aP2-nSREBP-lc mice. Even if there is 
increased muscle insulin sensitivity in the muscles of a6A2./7/;aP2-nSREBP-lc mice, it is 
possible that increased gluconeogenesis and hence increased hepatic glucose output 
might confound skeletal muscle insulin sensitivity resulting in the aggravated plasma 
glucose levels observed in these animals. It is also possible that decreased plasma insulin 
levels in afr//afr/;aP2-nSREBP-lc mice result in improved insulin sensitivity rather than 
P-cell failure. 
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Chapter 5: Leptin-mediated correction of insulin resistance in lipodystrophic 
mice 
Introduction 
Fat accumulation in peripheral insulin sensitive tissues such as liver, muscle and 
pancreatic (3-cells has been implicated in inducing insulin resistance in these tissues. Fat 
accumulation is suggested to interfere with insulin signaling in these tissues thus 
impairing insulin sensitivity (Shulman 2000; Unger 2003). aP2-nSREBP-lc mice are 
very insulin resistant as indicated by their glucose and insulin levels and their insulin 
unresponsiveness by insulin tolerance test. When muscle insulin sensitivity was studied 
in these animals, these animals had normal insulin receptor, IRS-1, IRS-2 and Glut4 
m R N A expression in this tissue. Moreover, they had a normal response to insulin-
stimulated glucose uptake in muscle (Shimomura et al. 1998). A physiological dose of 
peripheral leptin was shown to correct insulin resistance, diabetes and hepatic steatosis in 
these mice independent of food intake effects. Food restricted aP2-nSREBP-lc mice had 
decreased body weight and ameliorated hepatic steatosis with no improvement in insulin 
resistance (Shimomura et al. 1999). In both leptin-deficient ob/ob mice and in 
lipodystrophic aP2-nSREBP-lc mice, glycolytic enzymes such as glucokinase and 
pyruvate kinase as well as gluconeogenic enzymes are upregulated in liver. These genes 
are no longer sensitive to insulin's lowering effects however, leptin treatment lowers the 
expression of these genes to wild-type levels (Shimomura et al. 2000). Furthermore, 
IRS-2 m R N A and protein levels were decreased in aP2-nSREBP-lc lipodystrophic mice 
and insulin-stimulated Akt phosphorylation was impaired in these animals (Shimomura et 
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al. 2000). Leptin was also shown to improve insulin resistance and diabetes in 
lipodystrophic human patients (Oral et al. 2002). In these lipodystrophic patients, leptin 
was shown to increase both hepatic and muscle insulin sensitivity as well as decreasing 
triglyceride content in both tissues (Petersen et al. 2002). 
The mechanism by which leptin improves insulin resistance is not well 
understood. Leptin could improve insulin resistance by clearing all the lipids from 
peripheral tissues such as liver and muscle and hence making them insulin sensitive again 
or leptin could improve insulin sensitivity through other mechanisms independent of its 
lipid clearing effects. In these studies, we identified two suboptimal subcutaneous leptin 
doses, which improved hyperglycemia and hyperinsulinemia without correcting hepatic 
steatosis and with mild effects on SCD activity. These studies suggest that leptin may 
improve diabetes in lipodystrophic mice via an insulin-dependent pathway, which 
appears to be independent of its effects on SCD-1 and steatosis. 
Results 
Subcutaneous leptin dose response study 
The results from studies of aZ>y/aZ/;aP2-nSREBP-lc mice (Chapter 4) suggest 
that leptin's anti-diabetic effects are independent of its ability to clear lipid in liver and 
other tissues. In order to further explore this possibility and the underlying mechanism, 
we generated a dose response curve for subcutaneous leptin in aP2-nSREBP-lc mice. 
The objective of this study was to assess whether leptin's ability to improve diabetes was 
evident at the same or a different dose as its ability to reduce steatosis. We infused leptin 
at 12ng/hr, 25ng/hr, 50ng/hr and lOOng/hr with the highest dose being 200ng/hr, a dose 
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which has previously been shown to both improve diabetes and reduce steatosis 
(Shimomura et al. 1999). Body weight decreased 1.5% with the 50ng/hr leptin dose, 
6.7% with the lOOng/hr leptin dose and 10.5% with the 200ng/hr leptin dose (Figure 
5.1a). There was a significant decrease in food intake only with the 200ng/hr leptin dose 
(Figure 5.1b). Plasma leptin levels were raised to physiological levels only with the 
200ng/hr dose with intermediate increases following other doses (Figure 5.1c). Liver 
triglyceride levels were corrected to wild type levels at the 200ng/hr leptin dose with 
modest reductions at the lower infusion rates (Figure 5.1d). SCD activity was corrected 
to wild type levels only with the 200ng/hr leptin infusion (Figure 5.1e). 
While SCD activity and liver triglyceride levels were normalized only at the 
highest dose, there was a significant reduction in both plasma glucose and plasma insulin 
levels at the 50ng/hr, lOOng/hr and 200ng/hr leptin doses (Figure 5.1f-g). There was also 
a significant reduction in liver glycogen content at the 50ng/hr, lOOng/hr and 200ng/hr 
leptin doses (Figure 5.1h). Thus, leptin improves diabetes at doses that do not normalize 
hepatic steatosis or reduce SCD-1 activity to wild type levels. This suggests the 
possibility that leptin's antidiabetic effects are independent of its ability to repress SCD-1 
and reduce steatosis. 
Insulin signaling at a low dose that improves glucose levels 
In principal, leptin could improve diabetes by increasing glucose uptake or 
decreasing hepatic glucose output independent of insulin or by improving insulin signal 
transduction. To distinguish between these possibilities, we studied the effects of insulin 
in aP2-nSREBP-lc mice following treatment with a dose of peripheral leptin (50ng/hr) 
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Figure 5.1 Dose-response curve for leptin treatment. Leptin corrects 
hyperinsulinemia and hyperglycemia at leptin doses that have no effect 
on SCD activity and gross liver appearance (50 ng/h and 100 ng/h). 
(a) Liver triglyceride content, (b) SCD enzymatic activity measured in liver 
extracts of aP2-nSREBP-lc mice treated with several doses of subcutaneous 
leptin. (c and d) Plasma glucose and plasma insulin levels, respectively. 
Error bars indicate the SE; n = 3 for 12 ng/h and 25 ng/h leptin, and n - 4 
for 0 ng/h, 50 ng/h, 100 ng/h, and 200 ng/h leptin. *P < 0.005, 200 ng/h 
leptin dose vs. 0 ng/h dose. *P < 0.05, 50 ng/h leptin dose vs. 0 ng/h dose. 
that improves diabetes but does not correct steatosis or reduce SCD-1 activity to wild 
type levels (Figure 5.1). 
In the livers from lipodystrophic mice, there was a marked reduction in insulin-
stimulated insulin receptor substrate 2 (IRS-2) phosphorylation and a decrease in both 
IRS-2 associated phosphotidylinositol 3-kinase (PI 3-Kinase) activity and Akt activity 
compared to the livers from wild type animals (Figures 5.2a-c). Leptin treatment 
(50ng/hr) normalized insulin stimulated IRS-2 phosphorylation and IRS-2 associated PI 
3-Kinase activity and Akt activity in livers of lipodystrophic mice (Figure 5.2a-c). In 
skeletal muscles of the lipodystrophic mice, there was also a decrease in IRS-1 associated 
PI 3-Kinase activity and Akt activity. However in this tissue leptin treatment did not 
fully correct the attenuated response to insulin (Figure 5.2d-e). 
The improved insulin signaling in the livers of aP2-nSREBP-lc mice treated with 
50ng/hr leptin dose does not seem to be associated with liver fatty acyl CoA levels. Liver 
fatty acyl CoA levels in aP2-nSREBP-lc mice treated with 50ng/hr leptin dose were not 
significantly different from the levels in aP2-nSREBP-lc mice treated with PBS (Figure 
5.3a). Consistent with this data, muscle fatty acyl CoA levels were also not significantly 
different (Figure 5.3b). This suggests that 50ng/hr leptin dose improves insulin 
sensitivity in these animals independent of liver and muscle fatty acyl CoA levels and 
leptin's effects on insulin sensitivity are not merely through its lipid clearing effects in 
these insulin sensitive tissues. It is possible however that leptin changes the level of 
another lipid moiety, which might be important in insulin sensitivity. It is also possible 
that there is a threshold effect for plasma leptin levels as well as liver triglyceride content 
and hepatic SCD activity, which would suggest that plasma leptin levels above and 
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s h o w representative results of relative immunoblot analysis, and in the lower panels, error bars indicate the 
SE; n = 4. *P < 0.05. W T vs. aP2-nSREBP-lc; P < 0.05, aP2-nSREBP-lc vs. aP2-nSREBP-lc plus leptin. (d) 
PI3K activities associated with tyrosine-phosphorylated proteins in muscle, (e) In vitro A K T kinase activity in 
muscle. The upper panel shows representative results of immunoblot analysis, and in the lower panel, each 
bar represents the m e a n calculated from two independent experiments. IB, immunoblot; IP, 
immunoprecipitation; PY, phosphotyrosine; PI(3)P, Pl(3) phosphate. 
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Figure 5.3 Fatty acyl CoA analysis in the muscle and liver of aP2-nSREBP-lc mice treated 
with PBS (aP2-nSREBP-lc PBS), 50ng/hr leptin (aP2-nSREBP-lc Leptin) and untreatred 
wild type controls (WT). a. Fatty acyl CoA levels in liver, b. Fatty acyl CoA levels in muscle. 
Error bars indicated the SE; n=3 for WT, n-3 for aP2-nSREBP-lc PBS, n=6 for aP2-nSREBP-lc 
Leptin in (a) and n=4 for aP2-nSREBP-lc Leptin in (b). *P<0.05, W T vs aP2-nSREBP-lc PBS, 
#P<0.05, W T vs aP2-nSREBP-lc Leptin, %P<0.05, aP2-nSREBP-lc Leptin vs aP2-nSREBP-lc PBS. 
plasma triglyceride content and hepatic SCD activity below a certain threshold have an 
improving effect on insulin action. 
Cluster analysis of hepatic transcription profiles with several subcutaneous 
leptin doses 
In the leptin dose response study, we identified two leptin doses, which improve 
hyperglycemia and hyperinsulinemia without correcting hepatic steatosis. In order to 
identify genes important in leptin's insulin sensitizing effects, we then performed cluster 
analysis of hepatic gene expression in the leptin dose response study. This cluster 
analysis was similar to the cluster analysis previously described in WAT of leptin treated 
wild type mice over a period of time (Soukas et al. 2000). 
From this cluster analysis, we chose the analysis that has given us six clusters, 
three clusters of leptin induced genes and three clusters of leptin repressed genes. One of 
these clusters included genes that were induced at 50ng/hr leptin dose or higher 
(Appendix A; Figure 5.4a). This clustered contained several ESTs and some known 
genes such as angiogenin and hepatocyte nuclear factor 3y. The second cluster included 
genes that were mostly induced at 200ng/hr leptin dose (Appendix B; Figure 5.4b). This 
cluster included genes such as insulin-like growth factor binding protein-2 (IGFBP-2) 
and hepatic nuclear factor 6 (HNF6). The last cluster of induced genes included genes 
that were induced at all leptin doses (Appendix C; Figure 5.4c). This cluster also 
contained mostly ESTs, however, there were some known genes such as eukaryotic 
translation initiation factor IA. The first cluster of leptin-repressed genes included genes 
that were repressed at 50ng/hr leptin dose or higher (Appendix D; Figure 5.4d). This 
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cluster included genes such as gluthione s-transferase and monocarboxylate transporter 1. 
The second cluster contained genes that were mostly repressed at 200ng/hr leptin dose 
(Appendix E; Figure 5.4e). This cluster included genes such as cell death activator 
CIDE-A and malic enzyme. The last cluster contained genes that were repressed at all 
leptin doses (Appendix F; Figure 5.4f). This cluster contained genes such as a 
serine/threonine kinase sak-b. 
We then performed real time RT-PCR (Taqman) analysis to verify some of the 
genes that were present in our cluster analysis as well as other genes important in glucose 
metabolism. One of the genes that were downregulated at all leptin doses was a 
serine/threonine kinase, sak-b. Taqman analysis of this gene showed that sak mRNA 
levels were significantly lower in animals treated with 1 OOng/hr and 200ng/hr leptin dose 
compared to PBS treated animals (Figure 5.5a). HNF-6 was another leptin regulated 
gene, which was in a cluster of genes that were upregulated mainly at the 200ng/hr leptin 
dose. Taqman analysis of HNF-6 showed that there was a trend for this gene to be 
increased by leptin however this was not significant (Figure 5.5b). In order to determine 
if suboptimal leptin doses improved hyperglycemia and hyperinsulinemia in aP2-
nSREBP-lc mice by decreasing hepatic glucose output and suppressing gluconeogenesis, 
we measured mRNA levels of three key gluconeogenic enzymes. There was a significant 
reduction in glucose-6-phosphotase mRNA levels following both 50ng/hr leptin dose and 
200ng/hr leptin dose (Figure 5.5c). There was also a reduction in Fl,6BPase mRNA 
levels with 50ng/hr and 200ng/hr leptin doses however this was not significant (Figure 
5.5d). PEPCK mRNA levels on the other hand showed an increasing trend at the 50ng/hr 
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and 200ng/hr leptin doses but this increase was also not statistically significant (Figure 
5.5e). 
Discussion 
While SCD-1 deficiency reduced hepatic steatosis in lipodystropic mice, these 
animals remained severely diabetic (Chapter 4) (Asilmaz et al. 2004). Thus, reducing the 
liver triglyceride content of lipodystrophic mice was by itself insufficient to correct their 
diabetes. This suggested that leptin's antidiabetic effects are not simply a result of its 
ability to reduce triglyceride levels in peripheral tissues. This possibility is also 
suggested by our observation that leptin can correct diabetes and improve hepatic insulin 
sensitivity in lipodystrophic animals at doses that do not reduce SCD activity and correct 
hepatic steatosis. 
These suboptimal leptin doses could improve diabetes in lipodystrophy by an 
insulin-dependent or insulin-independent mechanism. The data presented here supports 
the former possibility and suggests that leptin treatment improves insulin signal 
transduction in liver. Leptin enhances IRS-2 phosphorylation, IRS-2 associated PI 3-
kinsase activity and Akt activity in livers of aP2-nSREBP-lc mice. This insulin 
sensitizing effect in liver seems to be SCD independent, since leptin can improve 
hyperglycemia and hyperinsulinemia at doses that do not correct SCD-1 expression and 
enzymatic activity to wild type levels. This suggests that other leptin regulated genes or 
pathways are necessary for leptin's insulin sensitizing effects. It is also possible that 
89 
there is a threshold effect of S C D activity on insulin action such that S C D activity below 
a certain threshold improves insulin action. 
In order to determine other leptin regulated genes and pathways that are important 
for leptin's insulin sensitizing effects, we used a clustering algorithm to cluster genes that 
responded to several leptin doses with a certain expression pattern (Soukas et al. 2000). 
This enabled us to identify pathway of genes regulated similarly by leptin or identify 
individual genes important in leptin's effects in lipodystrophy. In this clustering analysis, 
we analyzed genes in six clusters that might be important for leptin's effects. There were 
six clusters with three unique expression patterns since each pattern was both induced 
and repressed. In two of the clusters, expression of these genes were either induced or 
repressed at all doses of leptin suggesting that genes in these clusters might be very 
sensitive to leptin and hence might be important for leptin's actions. Sak-b, a 
serine/threonine kinase with an unknown function was in the cluster of genes whose 
expression was repressed at all leptin doses. Since activation of serine/threonine kinases 
are implicated in fatty acid induced insulin resistance in peripheral tissues (Shulman 
2000; Perseghin et al. 2003), leptin might be improving insulin sensitivity by 
downregulating serine/threonine kinases. In two other clusters, expression of genes was 
either induced or repressed at 50ng/hr or higher leptin doses. These clusters might 
contain genes that are important in leptin's insulin sensitizing effects since at the 50ng/hr 
and lOOng/hr doses, leptin was able to improve hyperinsulinemia and hyperglycemia. 
HNF3y was one of the genes whose expression was induced at 50ng/hr and higher leptin 
doses. This is a transcription factor which is implicated in glucose metabolism (Shen et 
al. 2001) therefore, it might be important in leptin's insulin sensitizing effects. In two 
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other clusters, gene expression was either induced or repressed mainly at 200ng/hr leptin 
dose. This leptin dose was able to correct both insulin resistance and hepatic steatosis of 
lipodystrophic animals therefore, these genes might be important for both leptin's insulin 
sensitizing and antisteatotic effects (Shimomura et al. 1999) (Chapter 3) (Asilmaz et al. 
2004). HNF6 is a transcription factor, which was induced mainly with 200ng/hr leptin 
dose. HNF6 might be important in glucose metabolism (Lannoy et al. 2002). Insulin-
like binding protein 2 (IGFBP-2) is another gene whose expression was induced at 
200ng/hr leptin dose. The role of this protein in leptin's effects remains unknown. In the 
cluster of genes repressed at 200ng/hr, there were genes that are already known to be 
important in obesity and glucose metabolism. These genes included cide-a, malic 
enzyme, glycerol-3-phosphate acyltransferase and glycerol-3-phosphate dehydrogenase. 
Cide-a knockout mice were shown to be resistant to diet induced obesity (Zhou et al. 
2003; Li 2004). Malic enzyme, gly cerol-3-phosphate acyltransferese and glycerol-3-
phosphate dehydrogenase are important in glucose metabolism. 
Real-time RT-PCR (Taqman) analysis of two key gluconeogenic genes, glucose-
6-phosphatase and Fl,6-bisPase showed that the mRNA levels for these genes were 
reduced at both 50ng/hr and 200ng/hr leptin dose, on the other hand, PEPCK levels were 
slightly elevated at 50ng/hr leptin dose but this increase was not significant. This might 
suggest that suboptimal leptin doses could improve insulin signaling and repress 
gluconeogenesis in liver and hence improve hyperglycemia and hyperinsulinemia with no 
significant improvement of hepatic steatosis. It is also known that a number of hormonal 
and nonhormonal factors regulate the transcription of these gluconeogenic enzymes 
which may also be regulated by nontranscriptional mechanisms. High insulin levels 
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downregulate glucose-6-phosphatase m R N A and PEPCK m R N A levels by PI-3K 
activation (Barthel and Schmoll 2003). High glucose on the other hand, is known to 
increase glucose-6-phosphatase mRNA and decrease PEPCK mRNA levels (Pilkis and 
Granner 1992). The observation that insulin action is improved at a dose of leptin as low 
as 50 ng/hr may simplify further efforts to elucidate the biochemical mechanism, since 
potentially confounding effects of this hormone on triglyceride levels and perhaps lipid 
metabolism would not be evident at this dose. 
The effects of chronic leptin treatment reported here are somewhat different from 
the acute effects of leptin. In previous studies, leptin was shown to acutely stimulate 
glucose metabolism in wild type mice by an insulin-independent mechanism and to 
acutely increase glucose turnover in ob/ob mice (Kamohara et al. 1997; Burcelin et al. 
1999). The basis for this difference is unknown but could relate to the differential effects 
of this hormone on liver before and after glycogen stores are depleted. 
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Chapter 6: Efferent signals mediating leptin's effects 
Introduction 
There is data suggesting that leptin has direct effects on peripheral tissues such as 
liver, muscle, heart and pancreatic (3-cells (Kieffer et al. 1997; Cohen et al. 2001; 
Atkinson et al. 2002; Minokoshi et al. 2002). However, several different lines of 
evidence suggest that the main site of leptin action is the brain (Halaas et al. 1997; Cohen 
et al. 2001; Asilmaz et al. 2004). Leptin is an afferent signal between peripheral tissues 
and brain. Leptin is suggested to act through the CNS in order to exert its effects on food 
intake, energy expenditure and other peripheral metabolic effects such as its effects on 
glucose and lipid metabolism. The efferent signals mediating leptin's peripheral effects 
are not very well understood. Leptin may affect glucose and lipid metabolism through 
hormonal effects or via neural effects. Sympathetic nervous system is suggested to be 
one of the efferent pathways mediating leptin s peripheral effects. Leptin was shown to 
increase sympathetic outflow and this effect of leptin was independent of its effects on 
food intake. Sympathetic nerve activity to peripheral tissues such as BAT, kidney, 
hindlimb and adrenal medulla increased following intravenous leptin treatment (Haynes 
et al. 1997a). It has been shown that leptin can no longer promote glucose uptake into 
peripheral tissues in denervated animals or in animals treated with (3-AR blockers (Haque 
et al. 1999). In denervated animals, leptin can no longer upregulate UCP-1 expression in 
BAT (Scarpace and Matheny 1998). A possible mechanism is suggested as follows: 
Leptin is secreted mainly from the WAT and it crosses the blood-brain barrier and acts on 
its receptors in the hypothalamus affecting neurotransmitters such as NPY, AGRP, MSH 
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and M C H . A G R P and M S H then act on melanocortin 4 (MC4) receptors in the 
hypothalamus hence stimulating sympathetic nerve activity on peripheral tissues (Lowell 
and Bachman 2003). 
Sympathetic nervous system was shown to affect glucose and lipid metabolism 
and these effects are probably mediated by hormones such as glucagon and epinephrine 
as well as direct innervation of peripheral tissues such as liver, adipose tissue and skeletal 
muscle (Nonogaki 2000). Sympathetic nervous system was shown to increase hepatic 
glucose production as well as glucose uptake into skeletal muscle, WAT and BAT. 
Moreover, sympathetic nervous system was also suggested to have effects on lipid 
metabolism such as increasing lipolysis in WAT and stimulating thermogenesis in BAT 
(Nonogaki 2000). Sympathetic nervous system may act either through the a-adrenergic 
receptors or P-adrenergic receptors on peripheral tissues. p-adrenergic receptors are 
implicated in regulating peripheral metabolism. 
There are three subtypes of p-adrenergic receptors (P-ARs), which are G-protein 
coupled receptors. These include PiAR, P2AR and p3AR. PiARs and p2ARs are widely 
expressed throughout different tissues of the body whereas p3ARs are almost exclusively 
expressed on adipocytes (Collins and Surwit 2001). All of these receptors are located on 
both WAT and BAT, the relative importance of each of these three receptors is not well 
established (Robidoux et al. 2004). In order to understand the function of these receptors 
in metabolism, knockouts of individual isoforms have been performed, however, these 
knockout mice did not have a significant metabolic or obese phenotype probably due to 
compensation by the other isoforms (Susulic et al. 1995; Rohrer et al. 1996; Revelli et al. 
1997; Chruscinski et al. 1999). P3-AR is mostly implicated in the regulation of energy 
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homeostasis, glucose and lipid metabolism as well as leptin signaling (Nonogaki 2000). 
When mice with a knockout of all three isoforms were generated (P-less mice), these 
animals were slightly heavier than their littermate controls on a regular chow diet 
however, they developed a more severe diet induced obesity on high fat diet compared 
with their littermate controls (Bachman et al. 2002). 
Here, we investigated the role of p-adrenergic receptors in leptin mediated body 
mass reduction and in mediating leptin's metabolic effects. We first treated p-less mice 
and their littermate controls with subcutaneous leptin either for 2-3 days or for 12 days. 
In these studies, we showed that p-adrenergic receptors are necessary for leptin mediated 
fat mass reduction. Moreover, we studied leptin regulated gene expression in peripheral 
tissues such as WAT, BAT, liver and muscle and showed that leptin acts through p-
adrenergic receptors in order to change the expression of certain genes in peripheral 
tissues. Our data suggested that sympathetic nervous system is one of the efferent 
pathways mediating leptin's peripheral effects. 
Results 
Attenuated leptin response in pMess mice 
In order to study the role of sympathetic nervous system in leptin's peripheral 
actions, we treated p-less mice and their littermate controls with subcutaneous leptin, 
subcutaneous PBS and a separate group was treated with subcutaneous PBS and at the 
same time was food restricted "pair-fed" to the leptin group as an extra control to 
differentiate between leptin's effects on food intake from its effects that are independent 
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of food intake (Halaas et al. 1997). There was a significant reduction in body weight and 
food intake in both p-less mice and their littermate controls treated with leptin. A similar 
decrease in both weight and food intake was also observed in the pair-fed groups. The 
decrease in body weight and food intake was lower in p-less mice compared to their 
littermate controls (Figure 6.1a). After 12 days of leptin treatment, even though there 
was a comparable weight loss between the P-less mice and their littermate controls, 
littermate control mice had almost no WAT left, whereas, p-less mice still had 
significantly more WAT (Figure 6.1b). This observation was further confirmed by body 
composition analysis, which showed that there was no difference in percent fat mass in p-
less mice treated with either leptin, PBS or pair-fed whereas there was a significant 
reduction in percent fat mass of littermate controls treated with leptin compared to PBS 
or pairfed controls (Figure 6.1c). Baseline leptin levels were slightly higher in p-less 
mice compared to their littermate controls and plasma leptin levels of wild type mice 
were higher than those of p-less mice following leptin treatment (data not shown). 
Sympathetic nervous system was also previously implicated in glucose 
homeostasis. We measured plasma insulin and glucose levels of P-less mice and their 
littermate controls following leptin and PBS treatment. After three days of leptin 
treatment, there was no significant difference in plasma glucose between leptin and PBS 
treatments either in p-less mice or their littermate controls. Plasma insulin levels were 
lower in both groups following leptin treatment however these differences were not 
significant. On the other hand, both plasma insulin and glucose levels were significantly 
reduced in wild type mice treated with leptin for 12 days compared to PBS treated mice 
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Figure 6.1 Attenuation in the leptin response in betaless mice. a. Weight curves and Food 
intake measurements of betaless and wild type (WT) mice treated with leptin, PBS or pairfed (PF) for 
12 days. b. Gross anatomy of betaless and W T mice follwoing 12 days of leptin treatment, c. Body 
composition analysis of betaless (KO) and W T mice following 12 days of leptin treatment. Error 
bars indicate the SE, n = 5 for both betaless and wild type groups. *P=0.05, betaless leptin vs 
betaless pbs and W T leptin vs. W T PBS. #P<0.00001 W T leptin vs W T PBS. %P=0.05 betaless leptin 
vs. W T leptin. 
whereas there was no significant difference in plasma insulin and glucose levels of p-less 
mice treated with either leptin or PBS (Figure 6.2a-b). 
Gene expression analysis in leptin treated P-less mice 
We then studied gene expression of a few genes in peripheral tissues, such as 
BAT and liver in p-less mice and their littermate controls in response to 2-3 days of 
leptin treatment. In liver, we studied the expression and activity of SCD-1, which is a 
leptin-regulated gene (Cohen et al. 2002). Both SCD-1 mRNA levels and SCD activity 
were higher in the livers of P-less mice compared to their littermate controls. There was 
a significant reduction in both SCD-1 mRNA levels and SCD activity following leptin 
treatment in both P-less mice and their littermate controls (Figure 6.3a-b). In BAT, we 
studied the expression of two genes, uncoupling protein 1 (UCP-1), which is part of the 
electron transport chain and is important for thermogenesis, and hormone sensitive lipase 
(HSL), which is involved in lipolysis. UCP-1 expression was significantly elevated in 
wild type mice treated with leptin compared to PBS treated controls whereas there was no 
increase in UCP-1 mRNA levels in p-less mice treated with leptin (Figure 6.3c). 
Similarly, HSL expression was also upregulated in wild type mice treated with leptin and 
there was no induction of HSL levels in leptin treated p-less mice (Figure 6.3d). 
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Discussion 
Sympathetic nervous system has been implicated in the regulation of energy 
homeostasis as well as in the regulation of other metabolic pathways such as glucose and 
lipid homeostasis (Nonogaki 2000). Genetically obese animals were shown to have 
decreased brown fat sympathetic activity as well as decreased thermogenesis (Himms-
Hagen 1989). Furthermore, P3-AR agonists were shown to increase energy expenditure 
(Arch and Kaumann 1993). Finally, mice lacking all three p-ARs failed to induce 
thermogenesis in BAT and hence developed diet-induced obesity on high fat diet 
(Bachman et al. 2002). Here, we investigated the role of sympathetic nervous system, 
specifically the role of p-ARs, in mediating leptin's peripheral effects. Our data suggests 
that sympathetic nervous system is necessary for leptin's effects on weight reduction and 
possibly on glucose metabolism. This conclusion is consistent with the data showing that 
leptin treatment increases sympathetic nerve activity to BAT, kidney, hind limb and 
adrenal gland in wild type animals. In addition, in leptin-deficient ob/ob mice, leptin 
administration increased energy expenditure partly through sympathetic nerve activity in 
BAT (Collins et al. 1996). Other studies also suggested that defective leptin signaling 
decreased sympathetic nerve activity while increasing parasympathetic nerve activity 
(Haynes et al. 1997b). 
Our data suggests that leptin reduces the expression of genes such as UCP-1 and 
HSL in BAT through p-adrenergic signaling thus regulating lipolysis and thermogenesis 
in this tissue. Previously, leptin was suggested to decrease food intake and at the same 
time increase energy expenditure and regulate glucose and lipid metabolisms through 
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autonomic nervous system (Friedman 2002b). p-ARs are thought to be important 
mediators of leptin's effects since, leptin may no longer induce glucose uptake into BAT 
either in sympathetic nerve denervated animals or in animals treated with P-AR blockers 
(Haque et al. 1999). Furthermore, leptin induced UCP-1 expression in BAT was also 
blunted in denervated animals suggesting that leptin mediated activation of the 
sympathetic nervous system induces UCP-1 activity in BAT hence increasing 
thermogenesis in this tissue (Scarpace and Matheny 1998). 
Our data also suggests that leptin might be influencing glucose metabolism 
through p-adrenergic stimulation. In wild type mice, leptin treatment for 12 days reduced 
both plasma insulin and glucose levels whereas it failed to do so in p-less mice. In 
general, obese humans and rodents have high plasma leptin levels, however, they are 
"resistant" to leptin's actions. In these individuals, decreased sympathetic outflow is 
suggested to impair glucose tolerance and lead to obesity. For example, in Pima Indians, 
Finns and in patients with morbid obesity, a missense mutation in P3-AR was associated 
with abdominal obesity and Type II diabetes (Clement et al. 1995; Walston et al. 1995; 
Widen et al. 1995). This suggests that impairment in leptin and/or in sympathetic 
nervous system signaling may predispose individuals to obesity and diabetes. Therefore, 
it is important to fully understand the efferent signals mediating leptin s peripheral 
actions in order to be able to develop better therapeutics for obesity and type II diabetes. 
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Chapter 7: Conclusion 
S u m m a r y of findings 
The studies in this thesis aim to understand the molecular mechanisms by which, 
leptin corrects insulin resistance and hepatic steatosis. We specifically studied leptin's 
effects mainly on liver as well as on muscle in lipodystrophic aP2-nSREBP-lc transgenic 
mice. These animals have metabolic abnormalities such as insulin resistance and hepatic 
steatosis associated with lipodystrophy (Shimomura et al. 1998). Peripheral leptin 
administration was shown to correct both of these metabolic abnormalities and leptin's 
effects are independent of its effects on food intake (Shimomura et al. 1999). 
Furthermore, leptin also corrects insulin resistance associated with lipodystrophy in 
humans (Oral et al. 2002; Petersen et al. 2002). However, neither the site nor the 
mechanism of leptin action in lipodystrophy is currently fully understood. In the absence 
of adipose tissue and/or adipokines such as leptin, triglycerides and fatty acids are 
accumulate in peripheral tissues such as liver, muscle, heart and pancreatic p-cells. 
Accumulation of triglycerides and fat in non-adipose tissues is suggested to lead to 
"lipotoxicity" hence interfering with the normal function of these tissues (Friedman 
2002a; Unger 2003). Fat accumulation in insulin sensitive peripheral tissues such as liver 
and muscle is also suggested to interfere with insulin signaling hence leading to insulin 
resistance (Shulman 2000). aP2-nSREBP-lc mice were shown to have impaired insulin 
signaling and an induction of gluconeogenic gene expression in liver (Shimomura et al. 
2000). Leptin's improvement of insulin action was also shown in other settings however, 
the basis for these effects are not fully understood (Kamohara et al. 1997; 
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Chinookoswong et al. 1999; Ogawa et al. 1999). The primary goal of this thesis was to 
understand the molecular basis for leptin-mediated correction of insulin resistance and 
hepatic steatosis. 
Initially, we were interested in understanding the site of leptin action in 
lipodystrophy. We wanted to know if leptin corrects hepatic steatosis and insulin 
resistance associated with lipodystrophy indirectly via the CNS or through direct effects 
on peripheral tissues (Chapter 3). Although a large number of reports suggested that the 
main site of leptin action is the brain and leptin exerts its metabolic effects indirectly via 
the CNS, there are other reports suggesting that leptin acts directly on peripheral tissues 
to exert its metabolic effects (Campfield et al. 1995; Halaas et al. 1997; Kieffer et al. 
1997; Cohen et al. 2001; Atkinson et al. 2002; Minokoshi et al. 2002). In order to 
determine the site of leptin action in lipodystrophy, we first treated aP2-nSREBP-lc mice 
with a low dose of ICV leptin. In this study, we showed that this dose of central leptin 
treatment was sufficient to correct the metabolic abnormalities associated with 
lipodystrophy as well as a much higher peripheral dose, suggesting that in lipodystrophy, 
leptin acts indirectly via the CNS (Chapter 3)(Asilmaz et al. 2004). In order to further 
determine whether leptin changes peripheral gene expression indirectly via the CNS or by 
direct effects on peripheral tissues, we compared hepatic and muscular gene expression 
from aP2-nSREBP-lc mice treated with ICV leptin and with subcutaneous leptin. This 
analysis revealed that there was a very strong correlation in the hepatic gene expression 
between ICV leptin and subcutaneous leptin treatments suggesting that leptin changes 
hepatic gene expression indirectly via the CNS. However, there was a low correlation in 
muscle gene expression between ICV leptin and subcutaneous leptin treatments, which 
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suggests that leptin might act directly on muscle to change gene expression in this tissue. 
However, our data also suggests that any direct peripheral leptin effects are not essential 
since ICV leptin treatment was able to completely correct the metabolic abnormalities in 
lipodystrophy. 
Our previous studies suggested that leptin acts directly on the brain to exert its 
metabolic effects via the CNS; however, the molecular mechanisms for leptin's actions in 
lipodystrophy were still not known. One of the leptin-regulated genes in the livers of 
aP2-nSREBP-lc mice following ICV and subcutaneous leptin treatments was SCD-1. 
Recently, SCD-1 was shown to be an important of mediator of leptin's metabolic effects. 
Deficiency of this enzyme was shown to improve both obesity and hepatic steatosis of 
ob/ob mice (Cohen et al. 2002). Furthermore, SCD-1 knockout mice were leaner than 
their littermate controls and they were shown to be resistant to diet-induced obesity 
(Ntambi et al. 2002). In order to inquire the role of SCD-1 in leptin-mediated correction 
of hepatic steatosis and insulin resistance in lipodystrophy, we studied this enzyme in the 
livers of aP2-nSREBP-lc mice (Chapter 4). We first showed that similar to ob/ob mice, 
in the livers of aP2-nSREBP-lc transgenic mice, both SCD-1 mRNA levels and activity 
were upregulated compared to their littermate controls and reduced to wild type levels 
following both ICV and subcutaneous leptin treatments. This suggests that leptin acts via 
the CNS in order to reduce SCD-1 gene expression in liver. In order to determine the 
contribution of SCD-1 upregulation to diabetes and hepatic steatosis associated with 
lipodystrophy, we generated aP2-nSREBP-lc mice lacking SCD-1, a bJ/abJ ;aP2-
nSREBP-lc mice. Even though these animals were still lipodystrophic, they had 
improved hepatic steatosis. We further investigated the mechanism by which SCD-1 
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deficiency improves hepatic steatosis and showed that in the absence of SCD-1, in the 
livers of abJ/abJ;aP2-nSREBP-lc mice, AMPK activity is increased which in turn 
inactivates ACC, reducing malonyl CoA levels thus increasing CPT-1 activity and 
mitochondrial p-oxidation. Despite improved hepatic steatosis, abJ/abJ;aP2-nSREBP-lc 
mice had increased plasma glucose levels, however, plasma insulin levels were lower in 
these animals. Gene expression analysis in the livers of these animals suggested that 
gluconeogenesis was higher in these animals compared to aP2-nSREBP-1 c mice, which 
might explain the aggravated diabetes. 
SCD-1 was previously implicated in improving insulin sensitivity by increasing 
insulin signaling in muscles of non-diabetic animals (Ntambi et al. 2002; Rahman et al. 
2003). Fat accumulation was suggested to impair insulin signaling in insulin sensitive 
peripheral tissues hence causing insulin resistance (Shulman 2000; Unger 2003). Despite 
the improved hepatic steatosis in abJ/abJ ;aP2-nSREBP-lc mice, these animals remained 
severely diabetic. These data suggested that leptin corrected insulin resistance in 
lipodystrophy independent of its effects on SCD-1 and possibly independent of its 
antisteatotic effects. In order to determine the mechanism of leptin-mediated correction 
of insulin resistance in lipodystrophic animals, we performed a peripheral dose response 
study in aP2-nSREBP-lc mice and studied insulin sensitivity and hepatic gene expression 
(Chapter 5). In this study, we identified two sub-optimal subcutaneous leptin doses, 
which improved hyperinsulinemia and hyperglycemia but did not correct hepatic 
steatosis. This observation further suggested that leptin might improve hyperinsulinemia 
and hyperglycemia independent of its antisteatotic effects. We further studied the 
mechanism of leptin mediated insulin sensitivity using one of these sub-optimal leptin 
106 
doses. W e studied insulin signaling in liver and muscle of aP2-nSREBP-lc mice 
following leptin treatment and showed that leptin improved hepatic insulin signaling but 
did not have a significant effect on muscle insulin signaling. To identify genes that were 
important for leptin's insulin sensitizing effects, we then performed cluster analysis of 
hepatic gene expression in aP2-nSREBP-lc mice treated with several peripheral leptin 
doses. In addition to other genes, we also identified two leptin regulated hepatocyte 
nuclear factors in this cluster analysis whose roles in leptin mediated correction of insulin 
resistance and hepatic steatosis are currently under study. 
Our results from Chapter 3 and several other reports suggest that leptin acts 
directly on the brain and it exerts its peripheral metabolic effects indirectly via the CNS 
(Halaas et al. 1997; Cohen et al. 2001; Asilmaz et al. 2004). The efferent pathways 
mediating leptin's peripheral effects however, are poorly understood. We examined the 
sympathetic nervous system, specifically p-AR activation as part of the efferent pathways 
mediating leptin s effects (Chapter 6). We first studied the response of p-less mice to 
leptin and showed that these animals had an attenuated response to leptin. We then 
studied leptin regulated gene expression in peripheral tissues of p-less mice and showed 
that leptin can no longer upregulate lipogenic genes such as HSL and thermogenic genes 
such as UCP-1 in BAT of these animals. These studies further suggested that 
sympathetic nervous system and p-AR activation is partly responsible for leptin's 
peripheral effects. 
In summary, in these studies, we have shown that leptin mediates its insulin 
sensitizing and antisteatotic effects indirectly via the CNS. SCD-1 is an important 
mediator of leptin's antisteatotic effects. Our data suggests that SCD-1 downregulation 
107 
improves hepatic steatosis by activating A M P K pathway, which activates fatty acid P-
oxidation although other mechanisms are also possible. The mechanism by which 
AMPK activation inhibits SCD activity is currently unknown. SCD-1 inhibition does not 
correct diabetes in the lipodystrophic aP2-nSREBP-lc. Therefore, it is likely that other 
genes are involved in leptin mediated correction of insulin resistance (Figure 7.1). 
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Figure 7.1 A proposed mechanism for leptin mediated correction of hepatic steatosis in 
lipodystrophic aP2-nSREBP-lc transgenic mice. SCD-1 deficiency results in increased AMPK 
phosphorylation and activity, A C C phorphorylation and inactivation, decreased malonyl-CoA levels 
and hence de-inhibiton of CPT-1 and an increase in fatty acyl CoA transport and b-oxiation in 
mitochondria (Taken from Dobrzyn et al. 2004)(Straight arrows do not necessarily suggest direct 
effects). 
Directions for future research 
The findings in this thesis generated many questions regarding leptin's effects in 
insulin sensitivity and hepatic steatosis, which remain to be answered. In regard to the 
site of leptin action in lipodystrophy, we have shown that brain is the main site of leptin 
action. Leptin mediates its peripheral actions indirectly via the CNS. Gene expression 
analysis of ICV leptin and peripheral leptin treated aP2-nSREBP-lc transgenic mice also 
revealed that hepatic gene expression is mediated via the CNS. On the other hand, gene 
expression analysis in muscle suggested that leptin might have direct effects in muscle. 
In order to test this possibility, we are currently generating muscle-specific knockout of 
leptin receptor using the Cre-lox technology (Cohen et al. 2001). Recently, leptin was 
suggested to directly activate AMPK in muscle (Minokoshi et al. 2002). Muscle-specific 
leptin receptor knockout mice will enable us to determine any direct leptin effects on this 
tissue. 
The efferent pathways mediating leptin's peripheral effects are currently 
unknown. As an attempt to further define the efferent pathways mediating leptin's 
effects, we studied P-less mice (Bachman et al. 2002). These studies suggested that 
leptin's effects are in part mediated by sympathetic nervous system and p-AR activation. 
These studies could further be extended to generating aP2-nSREBP-lc lipodystrophic 
mice with no P-ARs by crossing p-less mice to aP2-nSREBP-lc transgenic mice and 
studying the response of leptin in these animals. Gene expression analysis in peripheral 
tissues in these settings would also reveal leptin-regulated genes whose expression is 
regulated via the sympathetic nerve activation. Furthermore, parabiosis studies using 
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aP2-nSREBP-lc animals and p-less animals may be used to differentiate between the 
relative importance humoral factors versus the autonomic nervous system. Parabiosis 
studies between two aP2-nSREBP-lc transgenic mice where one is treated with ICV 
leptin might determine if a humoral efferent signal exists that controls leptin's insulin 
sensitizing and antisteatotic effects in these animals. Parabiosis between a p-less mice 
that is treated with ICV leptin and its littermate control might also be important in 
determining the existence of a humoral factor or the role of the sympathetic nervous 
system. Gene expression analysis in liver and other tissues would be useful in order to 
determine the efficacy of leptin action in these settings. Correlation analysis and cluster 
analysis used in this thesis may also be used in order to compare the relative efficacy of 
leptin treatment in each setting and to identify gene clusters that might be regulated via a 
specific efferent pathway. Since it would be very time consuming to breed aP2-nSREBP-
lc mice to p-less mice, lipodystrophy might be induced in the latter animals using a CLA 
diet, essentially generating lipodystrophic p-less mice which should exhibit the metabolic 
abnormalities, insulin resistance and hepatic steatosis, associated with lipodystrophy 
(Tsuboyama-Kasaoka et al. 2000). Leptin treatment of these animals would then reveal 
the significance of P-AR activation in leptin's effects. 
SCD-1 is an important mediator of leptin's weight reducing and antisteatotic 
effects (Cohen et al. 2002). Our data showed that leptin acts via the CNS to inhibit SCD-
1 activity and hence in part mediates its antisteatotic effects by inhibiting this enzyme. 
Currently, the exact mechanism by which leptin inhibits SCD-1 is not known. However, 
we have shown that leptin treatment of p-less mice also have decreased SCD activity in 
liver suggesting that the efferent pathways regulating this enzyme are independent of p-
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A R activation. Previously suggested parabiosis experiments might provide evidence for 
a humoral signal for SCD-1 regulation. In these experiments, leptin-regulated genes such 
as SCD-1 and others might be used as markers for leptin action. 
Our data suggested that SCD-1 is one of the mediators of leptin's antisteatotic 
effects in lipodystrophy. Our data further suggested that SCD-1 deficiency acts by 
increasing AMPK phosphorylation, which has an end result of increasing fatty acid 
oxidation in liver. This is also consistent with the data from SCD-1 knockout mice and 
ob/ob mice lacking SCD-1, abJ/abJ;ob/ob mice (Dobrzyn et al. 2004). It has previously 
been shown that AMPK phosphorylation increases its enzymatic activity however, we 
have not yet measured AMPK activity in the livers of a£/AZ/;aP2-nSREBP-lc mice 
therefore, AMPK activity needs to be measured in the livers of these animals. Moreover, 
fatty acid p-oxidation rate also needs to be determined in the livers of these mice. We 
would like to measure the palmitic acid incorporation into lipids in order to show that this 
is downregulated in the livers of abJ/abJ,aP2-n§REBP-\c mice and palmitoyl-CoA 
oxidation in mitochondria to show that this is upregulated in the livers of these mice as 
our data predicts. The mechanism by which SCD-1 deficiency leads to increased AMPK 
phosphorylation and activation in liver is currently not known. Leptin was shown to 
directly and indirectly increase AMPK phosphorylation and fatty acid oxidation in 
muscle (Minokoshi et al. 2002). However in heart, leptin was shown to increase fatty 
acid oxidation independent of AMPK (Atkinson et al. 2002). The fact that AMPK 
phosphorylation is increased in the absence of leptin in abJ/abJ;aP2-x\S,REBP-\c mice 
suggests that AMPK activation is independent of leptin. Moreover, SCD-1 deficiency's 
effects on steatosis in other tissues such as heart and skeletal muscle of abJ/abJ\aP2-
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nSREBP-lc mice is still unknown and these are currently under investigation. Based on 
our previous data, we expect to observe increased fatty acid P-oxidation and reduced 
steatosis in these tissues in the absence of SCD-1. 
Despite the improved hepatic steatosis in a.///a6'7;aP2-nSREBP-lc mice, these 
animals were still severely diabetic, they had higher plasma glucose levels compared to 
aP2-nSREBP-lc mice. Initial gene expression analysis in liver suggested that these 
animals might have increased gluconeogenesis, which would explain the aggravated 
diabetes. In order to prove this, it is necessary to study these animals under euglycemic-
hyperinsulinemic clamp conditions. These clamp studies would determine if there is 
increased hepatic glucose output in these animals. Fat accumulation in peripheral tissues 
is suggested to impair insulin signaling and hence lead to insulin resistance (Shulman 
2000). If this hypothesis is correct, since SCD-1 deficiency improves steatosis, this 
implicates that it would also improve insulin sensitivity. SCD-1 deficiency was shown to 
improve insulin sensitivity and increase insulin signaling in the muscles of nondiabetic 
animals (Ntambi et al. 2002; Rahman et al. 2003). It is therefore necessary to study 
insulin signaling in the muscles of a6J/.a£/;aP2-nSREBP-lc mice in order to determine if 
insulin signaling in muscle is also improved in these diabetic animals. It is possible that 
insulin signaling and sensitivity is improved in the muscles of a6y/afr/;aP2-nSR£BP-lc 
mice however, due to impaired insulin sensitivity and increased gluconeogenesis in liver, 
these animals are still diabetic. The euglycemic-hyperinsulinemic clamp studies in these 
animals, will also determine skeletal muscle insulin sensitivity by measuring glucose 
uptake into this tissue. In the livers of a6y/a6'/;aP2-nSREBP-lc mice, we have shown that 
fatty acid content is lower and saturated fatty acids are increased compared to 
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monounsaturated fatty acids, however, we have not performed detailed analysis of fatty 
acyl CoAs or other lipid moieties either in livers or muscles of these animals in order to 
determine if any of these were elevated compared to wild type levels which could 
possibly lead to insulin resistance. 
Even though plasma glucose levels were severely elevated in abJ/abJ;aP2-
nSREBP-lc mice, plasma insulin levels were significantly lower than their aP2-nSREBP-
lc littermate controls. Since these animals are severely diabetic, the decreased insulin 
levels suggest that there is possibly p-cell failure in these animals. The role of SCD-1 in 
pancreatic p-cells is currently not known. It has been previously suggested that 
accumulation of saturated fatty acids in a cell can lead to apoptosis (Listenberger et al. 
2003). In order to prove this, we will study the pancreas of a^AZ/;aP2-nSREBP-lc mice 
with immunofluorecence for insulin and glucagon and compare the number of p-cells in 
these animals to their littermate controls. It is however possible that there is no P-cell 
failure in these animals but the decreased plasma insulin levels are suggestive of 
improved insulin resistance. This possibility will also be answered by the studies 
suggested above. 
Humans have a single SCD gene, which has highest homology to the murine 
SCD-1 gene (Ntambi and Miyazaki 2003). It is necessary to study the role of SCD 
downregulation by leptin in lipodystrophic patients. SCD mRNA levels and activity 
needs to be measured in lipodystrophic patients before and after leptin treatment. 
Furthermore, global gene expression profiling using microarray analysis of liver and 
skeletal muscle biopsies of lipodystrophic patients before and after leptin treatment 
would reveal all of the leptin regulated genes in humans which are essential for leptin's 
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insulin sensitizing and antisteatotic effects in these patients. The comparison of these 
human leptin-regulated genes to murine leptin-regulated genes would be of great interest 
in terms of translating this research to humans. 
Our data from the peripheral leptin dose response study suggested that in aP2-
nSREBP-lc mice, leptin could improve liver insulin signaling at a dose, which did not 
correct hepatic steatosis. Liver gene expression analysis further suggested that this leptin 
dose decreased gluconeogenic gene expression. In order to be able to understand the 
insulin sensitizing effects of this dose of leptin, it is necessary to study aP2-nSREBP-lc 
animals treated with this leptin dose under euglycemic-hyperinsulinemic clamp 
conditions. This will provide us a better understanding of leptins effects on muscle 
glucose uptake versus its effects on hepatic glucose output. Furthermore, cluster analysis 
of gene expression in the livers of aP2-nSREBP-lc transgenic mice treated with several 
different doses of peripheral leptin, which have different physiological effects, would be 
useful in identifying genes in different pathways, which mediate leptin's metabolic 
effects. Some of the genes in these clusters are already known to be important in obesity 
and diabetes however, there are several other genes whose functions are either unknown 
or their role in obesity and diabetes have not been studied. For example, one of the 
leptin-regulated genes in these clusters was a serine/threonine kinase, sak-b. This gene 
was upregulated in the livers of aP2-nSREBP-lc mice and it was downregulated by leptin 
treatment. The function of this gene in leptin's metabolic effects is currently under 
investigation. Fat accumulation in insulin sensitive peripheral tissues such as liver and 
muscle were shown to impair insulin signaling by activating serine/threonine kinases that 
phosphorylate IRS molecules on serine/threonine residues hence impairing insulin 
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signaling and leading to insulin resistance in these tissues (Shulman 2000). It is possible 
that leptin inactivates these serine/threonine kinases hence improving insulin signaling in 
these tissues independent of its antisteatotic effects. It is also possible that leptin might 
activate an inhibitor of serine/threonine kinases or activate a phosphatase, which would 
explain its insulin sensitizing effects despite intracellular fat accumulation. Two other 
interesting genes in two separate clusters were HNF3y and HNF6. Both of these genes 
were upregulated by leptin in the livers of aP2-nSREBP-lc mice. The function of these 
genes is currently under investigation by crossing FINF3y and FINF6 knockout mice to 
aP2-nSREBP-lc transgenic mice and studying the response of these transgenic-knockout 
mice to leptin. 
A possible mechanism for the antidiabetic effects of leptin has been provided with 
the identification of the Foxa2 transcription factor as a component of the signal 
transduction pathway activated by insulin. In recent studies, Foxa2 was shown to be an 
important regulator of adipocyte differentiation and metabolism (Wolfrum et al. 2003b). 
Furthermore, it was shown that insulin phosphorylates Foxa2, which leads to its 
exclusion out of the nucleus where it can no longer activate its target genes (Wolfrum et 
al. 2003a). Studies of Foxa2 localization showed that Foxa2 is localized in the cytoplasm 
in lipodystrophic aP2-nSREBP-lc transgenic mice (C. Wolfrum and M. Stoffel 
unpublished results). Furthermore, a constitutively active Foxa2 was shown to improve 
both hepatic steatosis and insulin sensitivity in aP2-nSREBP-lc transgenic mice (C. 
Wolfrum and M. Stoffel unpublished results). It will therefore be relevant to determine 
Foxa2 localization in abJ/abJ;aP2-SREBP-\c and treat these mice with the constitutively 
active Foxa2 adenovirus to determine if constitutively active Foxa2 would also improve 
116 
the diabetic phenotype of abJ/abJ;aP2-SREBP-\c mice. Furthermore, it would be of 
interest to compare gene expression profiles between aP2-nSREBP-lc mice treated with 
leptin, treated with constitutively active Foxa2 and aP2-nSREBP-lc mice with SCD-1 
deficiency in order to identify genes specifically important for insulin resistance, hepatic 
steatosis or both. 
Conclusion 
Type II diabetes mellitus which is often associated with obesity has become a 
worldwide epidemic in the past few decades. Type II diabetes is a complex disease 
where several genes interact with each other and with environmental factors to mediate 
the pathogenesis of the disease. Leptin was shown to ameliorate Type II diabetes 
associated with rare leptin deficiency syndromes of obesity and lipodystrophy in humans. 
However, the majority of individuals with obesity-associated Type II diabetes, is not 
leptin deficient, but have high plasma leptin levels due to increased adiposity. The 
molecular basis for leptin's metabolic effects is not well understood. Defining the 
molecular basis for leptin's antidiabetic effects in rare forms of leptin deficiency 
syndromes associated with Type II diabetes would be helpful for identifying genes that 
are important in glucose and lipid metabolism. These genes might then be used as drug 
targets in order to treat common forms of Type II diabetes. 
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Figure 5.4 Cluster analysis of hepatic gene expression in 
aP2-nSREBP-lc mice treated with PBS, 12ng/hr, 25ng/hr, 50ng/hr, 
lOOng/hr and 200ng/hr subcutaneous leptin. a. Genes induced at 
50ng/hr or higher leptin doses. 
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aP2-nSREBP-lc mice treated with PBS, 12ng/hr, 25ng/hr, 50ng/hr, 
lOOng/hr and 200ng/hr subcutaneous leptin. b. Genes induced 
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Figure 5.4 Cluster analysis of hepatic gene expression in aP2-nSREBP-lc 
mice treated with PBS, 12ng/hr, 25ng/hr, 50ng/hr, lOOng/hr and 200ng/hr 
subcutaneous leptin. c. Genes induced at all of the leptin doses. 
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Figure 5.4 Cluster analysis of hepatic gene expression in 
aP2-nSREBP-lc mice treated with PBS, 12ng/hr, 25ng/hr, 50ng/hr, 
lOOng/hr and 200ng/hr subcutaneous leptin. d. Genes repressed at 
50ng/hr or higher leptin doses. 
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Figure 5.4 Cluster analysis of hepatic gene expression in 
aP2-nSREBP-lc mice treated with PBS, 12ng/hr, 25ng/hr, 50ng/hr, 
lOOng/hr and 200ng/hr subcutaneous leptin. e. Genes repressed 
mostly at 200ng/hr leptin dose. 
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Figure 5.4 Cluster analysis of hepatic gene expression in 
aP2-nSREBP-lc mice treated with PBS, 12ng/hr, 25ng/hr, 50ng/hr, 
lOOng/hr and 200ng/hr subcutaneous leptin. f. Genes repressed at 
all leptin doses. 
